BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J, Gourgou-bourgade S, de la Fouchardière C, Bennouna J, Bachet J, Khemissa-akouz F, Péré-vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-grillot C, Ducreux M. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med 2011;364:1817-25. [DOI: 10.1056/nejmoa1011923] [Cited by in Crossref: 3872] [Cited by in F6Publishing: 2101] [Article Influence: 352.0] [Reference Citation Analysis]
Number Citing Articles
1 Logan K, Pearson F, Kenny RP, Pandanaboyana S, Sharp L. Are older patients less likely to be treated for pancreatic cancer? A systematic review and meta-analysis. Cancer Epidemiol 2022;80:102215. [PMID: 35901624 DOI: 10.1016/j.canep.2022.102215] [Reference Citation Analysis]
2 Hanoun N, Gayral M, Pointreau A, Buscail L, Cordelier P. Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. Hum Gene Ther. 2016;27:184-192. [PMID: 26731312 DOI: 10.1089/hum.2015.151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
3 Saung MT, Zheng L. Current Standards of Chemotherapy for Pancreatic Cancer. Clin Ther 2017;39:2125-34. [PMID: 28939405 DOI: 10.1016/j.clinthera.2017.08.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
4 Harper MM, Lin M, Qasem SA, Patel RA, Cavnar MJ, Pandalai PK, Gao M, Kim J. Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Progression. Cancers 2022;14:3051. [DOI: 10.3390/cancers14133051] [Reference Citation Analysis]
5 Yanai Y, Makihara RA, Matsunaga N, Shimizu R, Tominaga S, Hoshino S, Nishibuchi Y, Maruki Y, Ohba A, Shimizu K, Okusaka T. A feasibility study of a peer discussion group intervention for patients with pancreatobiliary cancer and their caregivers. Palliat Support Care 2021;:1-8. [PMID: 34593073 DOI: 10.1017/S1478951521001474] [Reference Citation Analysis]
6 Wei D, Parsels LA, Karnak D, Davis MA, Parsels JD, Marsh AC, Zhao L, Maybaum J, Lawrence TS, Sun Y. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clin Cancer Res. 2013;19:4422-4432. [PMID: 23780887 DOI: 10.1158/1078-0432.ccr-13-0788] [Cited by in Crossref: 63] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
7 Yin Z, Zhou Y, Hou B, Ma T, Yu M, Zhang C, Lu X, Jian Z. Revision of Surgical Margin under Frozen Section to Achieve R0 Status on Survival in Patients with Pancreatic Cancer. J Gastrointest Surg 2018;22:1565-75. [PMID: 29777452 DOI: 10.1007/s11605-018-3806-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ardalan B, Azqueta J, Sleeman D. Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies. J Pancreat Cancer 2021;7:65-70. [PMID: 34901697 DOI: 10.1089/pancan.2021.0006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pelzer U, Klein F, Bahra M, Sinn M, Dörken B, Neuhaus P, Meyer O, Riess H. Blood group determinates incidence for pancreatic cancer in Germany. Front Physiol 2013;4:118. [PMID: 23745115 DOI: 10.3389/fphys.2013.00118] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
10 Johnson B, Vanderwalde A, Javadi N, Feldman R, Reddy SB. Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy. J Gastrointest Oncol 2016;7:E6-E12. [PMID: 27034805 DOI: 10.3978/j.issn.2078-6891.2015.091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Ray P, Nair G, Ghosh A, Banerjee S, Golovko MY, Banerjee SK, Reindl KM, Mallik S, Quadir M. Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer. J Cell Commun Signal 2019;13:407-20. [PMID: 30915617 DOI: 10.1007/s12079-019-00514-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
12 Khan S, Ebeling MC, Chauhan N, Thompson PA, Gara RK, Ganju A, Yallapu MM, Behrman SW, Zhao H, Zafar N. Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Cancer Res. 2015;75:2292-2304. [PMID: 25840985 DOI: 10.1158/0008-5472.can-14-2397] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
13 Fogel EL, Shahda S, Sandrasegaran K, DeWitt J, Easler JJ, Agarwal DM, Eagleson M, Zyromski NJ, House MG, Ellsworth S, El Hajj I, O'Neil BH, Nakeeb A, Sherman S. A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. Am J Gastroenterol. 2017;112:537-554. [PMID: 28139655 DOI: 10.1038/ajg.2016.610] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 11.6] [Reference Citation Analysis]
14 Kozak GM, Epstein JD, Deshmukh SP, Scott BB, Keith SW, Lavu H, Yeo CJ, Winter JM. Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer. J Gastrointest Surg 2018;22:288-94. [PMID: 29139084 DOI: 10.1007/s11605-017-3595-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
15 Broekgaarden M, Rizvi I, Bulin AL, Petrovic L, Goldschmidt R, Massodi I, Celli JP, Hasan T. Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids. Oncotarget 2018;9:13009-22. [PMID: 29560127 DOI: 10.18632/oncotarget.24425] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
16 Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012;1:179-88. [PMID: 22720239 DOI: 10.4161/onci.1.2.19026] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 80.0] [Reference Citation Analysis]
17 Dodhiawala PB, Khurana N, Zhang D, Cheng Y, Li L, Wei Q, Seehra K, Jiang H, Grierson PM, Wang-Gillam A, Lim KH. TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations. J Clin Invest. 2020;130:4771-4790. [PMID: 32573499 DOI: 10.1172/jci137660] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
18 Sawada M, Kasuga A, Mie T, Furukawa T, Taniguchi T, Fukuda K, Yamada Y, Takeda T, Kanata R, Matsuyama M, Sasaki T, Ozaka M, Sasahira N. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer 2020;20:449. [PMID: 32434547 DOI: 10.1186/s12885-020-06945-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
19 Rapposelli IG, Zampiga V, Cangini I, Arcangeli V, Ravegnani M, Valgiusti M, Pini S, Tamberi S, Bartolini G, Passardi A, Martinelli G, Calistri D, Frassineti GL, Falcini F, Danesi R. Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer. BMC Cancer 2021;21:611. [PMID: 34034685 DOI: 10.1186/s12885-021-08368-5] [Reference Citation Analysis]
20 Hennig A, Wolf L, Jahnke B, Polster H, Seidlitz T, Werner K, Aust DE, Hampe J, Distler M, Weitz J, Stange DE, Welsch T. CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids. Stem Cells Int 2019;2019:1024614. [PMID: 31191661 DOI: 10.1155/2019/1024614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
21 Chang CF, Huang PW, Chen JS, Chen YY, Lu CH, Chang PH, Hung YS, Chou WC. Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Cancers (Basel) 2019;11:E57. [PMID: 30634387 DOI: 10.3390/cancers11010057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
22 Stewart BA, Adjei A, Zhang X, Oxenberg JC. Metastatic adenocarcinoma of the pancreas presents as metastases to the axillary/supraclavicular region as the first sign of the disease. Ann Hepatobiliary Pancreat Surg 2017;21:247-51. [PMID: 29264591 DOI: 10.14701/ahbps.2017.21.4.247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
23 Dhillon H, Mamidi S, McClean P, Reindl KM. Transcriptome Analysis of Piperlongumine-Treated Human Pancreatic Cancer Cells Reveals Involvement of Oxidative Stress and Endoplasmic Reticulum Stress Pathways. J Med Food 2016;19:578-85. [PMID: 27119744 DOI: 10.1089/jmf.2015.0152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
24 Tummers WS, Willmann JK, Bonsing BA, Vahrmeijer AL, Gambhir SS, Swijnenburg RJ. Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer. Pancreas 2018;47:675-89. [PMID: 29894417 DOI: 10.1097/MPA.0000000000001075] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
25 Marin JJG, Monte MJ, Macias RIR, Romero MR, Herraez E, Asensio M, Ortiz-rivero S, Cives-losada C, Giacomo SD, Gonzalez-gallego J, Mauriz JL, Efferth T, Briz O. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers. Cancers 2022;14:3524. [DOI: 10.3390/cancers14143524] [Reference Citation Analysis]
26 Pipas JM, Zaki BI, McGowan MM, Tsapakos MJ, Ripple GH, Suriawinata AA, Tsongalis GJ, Colacchio TA, Gordon SR, Sutton JE. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Ann Oncol. 2012;23:2820-2827. [PMID: 22571859 DOI: 10.1093/annonc/mds109] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
27 Ruivo CF, Bastos N, Adem B, Batista I, Duraes C, Melo CA, Castaldo SA, Campos-Laborie F, Moutinho-Ribeiro P, Morão B, Costa-Pinto A, Silva S, Osorio H, Ciordia S, Costa JL, Goodrich D, Cavadas B, Pereira L, Kouzarides T, Macedo G, Maio R, Carneiro F, Cravo M, Kalluri R, Machado JC, Melo SA. Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression. Gut 2022:gutjnl-2021-324994. [PMID: 35012996 DOI: 10.1136/gutjnl-2021-324994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Satoi S, Yamamoto T, Yamaki S, Sakaguchi T, Sekimoto M. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2020;4:6-13. [PMID: 32021953 DOI: 10.1002/ags3.12295] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
29 Granata V, Fusco R, Setola SV, Piccirillo M, Leongito M, Palaia R, Granata F, Lastoria S, Izzo F, Petrillo A. Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy. World J Gastroenterol 2017; 23(26): 4767-4778 [PMID: 28765698 DOI: 10.3748/wjg.v23.i26.4767] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 24] [Article Influence: 6.6] [Reference Citation Analysis]
30 Yoo B, Jordan VC, Sheedy P, Billig AM, Ross A, Pantazopoulos P, Medarova Z. RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy. Sci Rep 2019;9:4712. [PMID: 30886310 DOI: 10.1038/s41598-019-41251-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
31 Pigula M, Mai Z, Anbil S, Choi MG, Wang K, Maytin E, Pogue B, Hasan T. Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel. Cancers (Basel) 2021;13:5781. [PMID: 34830934 DOI: 10.3390/cancers13225781] [Reference Citation Analysis]
32 Mahalingam D, Goel S, Aparo S, Patel Arora S, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A, Coffey M, Nawrocki ST, Nuovo G, Mita MM. A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E160. [PMID: 29799479 DOI: 10.3390/cancers10060160] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 12.5] [Reference Citation Analysis]
33 Bai C, Zhang X, Yang D, Li D, Feng H, Li Y. Clinical Analysis of Bloodstream Infection of Escherichia coli in Patients with Pancreatic Cancer from 2011 to 2019. Can J Infect Dis Med Microbiol 2022;2022:1338188. [PMID: 35340919 DOI: 10.1155/2022/1338188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Bailey KL, Carlson MA. Porcine Models of Pancreatic Cancer. Front Oncol 2019;9:144. [PMID: 30915276 DOI: 10.3389/fonc.2019.00144] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
35 Kanji ZS, Gallinger S. Diagnosis and management of pancreatic cancer. CMAJ. 2013;185:1219-1226. [PMID: 23610017 DOI: 10.1503/cmaj.121368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
36 Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, Brown L, Lewis A, Davies G, Morrow M, Wilkinson RW. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget 2016;7:18508-20. [PMID: 26918344 DOI: 10.18632/oncotarget.7610] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 10.2] [Reference Citation Analysis]
37 Michelakos T, Sekigami Y, Kontos F, Fernández-Del Castillo C, Qadan M, Deshpande V, Ting DT, Clark JW, Weekes CD, Parikh A, Ryan DP, Wo JY, Hong TS, Allen JN, Catalano O, Warshaw AL, Lillemoe KD, Ferrone CR. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. J Gastrointest Surg 2021. [PMID: 33501584 DOI: 10.1007/s11605-020-04897-9] [Reference Citation Analysis]
38 Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol 2019;11:1758835919875568. [PMID: 31598142 DOI: 10.1177/1758835919875568] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 15.3] [Reference Citation Analysis]
39 Van Cutsem E, Li CP, Nowara E, Aprile G, Moore M, Federowicz I, Van Laethem JL, Hsu C, Tham CK, Stemmer SM. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Br J Cancer. 2014;111:2067-2075. [PMID: 25247318 DOI: 10.1038/bjc.2014.494] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
40 Du L, DeFoe M, Ruzinova MB, Olsen JR, Wang-Gillam A. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:717-26. [PMID: 26226906 DOI: 10.1016/j.hoc.2015.04.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
41 Beutel AK, Schütte L, Scheible J, Roger E, Müller M, Perkhofer L, Kestler AMTU, Kraus JM, Kestler HA, Barth TFE, Lemke J, Kornmann M, Ettrich TJ, Gout J, Seufferlein T, Kleger A. A Prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Cancers (Basel) 2021;13:2539. [PMID: 34064221 DOI: 10.3390/cancers13112539] [Reference Citation Analysis]
42 Latchana N, Davis L, Coburn NG, Mahar A, Liu Y, Hammad A, Kagedan D, Elmi M, Siddiqui M, Earle CC, Hallet J. Population-based study of the impact of surgical and adjuvant therapy at the same or a different institution on survival of patients with pancreatic adenocarcinoma. BJS Open 2019;3:85-94. [PMID: 30734019 DOI: 10.1002/bjs5.50115] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Barros AG, Pulido CF, Machado M, Brito MJ, Couto N, Sousa O, Melo SA, Mansinho H. Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). Int J Oncol 2021;59:110. [PMID: 34859257 DOI: 10.3892/ijo.2021.5290] [Reference Citation Analysis]
44 Wang K, Baldwin GS, Nikfarjam M, He H. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World J Gastroenterol 2018; 24(33): 3709-3723 [PMID: 30197477 DOI: 10.3748/wjg.v24.i33.3709] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
45 Miura Y, Ando M, Yamazaki K, Hironaka S, Boku N, Muro K, Hyodo I. Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2). Support Care Cancer 2021;29:3715-23. [PMID: 33200233 DOI: 10.1007/s00520-020-05891-2] [Reference Citation Analysis]
46 Haque MR, Wessel CR, Leary DD, Wang C, Bhushan A, Bishehsari F. Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment. Microsyst Nanoeng 2022;8:36. [PMID: 35450328 DOI: 10.1038/s41378-022-00370-6] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 Ranieri G, Laface C. Loco-Regional and Systemic Chemotherapies for Hepato-Pancreatic Tumors: Integrated Treatments. Cancers (Basel) 2020;12:E2737. [PMID: 32987630 DOI: 10.3390/cancers12102737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Rademaker G, Hennequière V, Brohée L, Nokin MJ, Lovinfosse P, Durieux F, Gofflot S, Bellier J, Costanza B, Herfs M, Peiffer R, Bettendorff L, Deroanne C, Thiry M, Delvenne P, Hustinx R, Bellahcène A, Castronovo V, Peulen O. Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness. Oncogene 2018;37:4398-412. [PMID: 29720728 DOI: 10.1038/s41388-018-0287-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
49 Kim H, Morgan DE, Schexnailder P, Navari RM, Williams GR, Bart Rose J, Li Y, Paluri R. Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom: A Pilot Study. Invest Radiol 2019;54:16-22. [PMID: 30138218 DOI: 10.1097/RLI.0000000000000505] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
50 Van Audenaerde JRM, De Waele J, Marcq E, Van Loenhout J, Lion E, Van den Bergh JMJ, Jesenofsky R, Masamune A, Roeyen G, Pauwels P, Lardon F, Peeters M, Smits ELJ. Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget. 2017;8:56968-56979. [PMID: 28915646 DOI: 10.18632/oncotarget.18185] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
51 Du Y, Bai X, Yang W, Zhang Z, Wang S, Wu W, Yan K, Chen M. Percutaneous ultrasound-guided radiofrequency ablation for patients with liver metastasis from pancreatic adenocarcinoma. International Journal of Hyperthermia 2022;39:517-24. [DOI: 10.1080/02656736.2022.2048907] [Reference Citation Analysis]
52 Wen CL, Huang K, Jiang LL, Lu XX, Dai YT, Shi MM, Tang XM, Wang QB, Zhang XD, Wang PH, Li HT, Ruan XX, Wang LW, Wang XJ, Wang Q, Lu W, Xiang XQ, Sun X, Xu YH, Lai LH, Zhan Q, Li HW, Peng CH, Chen J, Huang JY, Ye DY, Chen SJ, Chen Z, Li M, Fang Y, Shen BY, Zhou L. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 2019;116:23264-73. [PMID: 31662475 DOI: 10.1073/pnas.1914557116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
53 Tiffon C. Defining Parallels between the Salivary Glands and Pancreas to Better Understand Pancreatic Carcinogenesis. Biomedicines 2020;8:E178. [PMID: 32604970 DOI: 10.3390/biomedicines8060178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Maggino L, Vollmer CM Jr. Recent Advances in Pancreatic Cancer Surgery. Curr Treat Options Gastroenterol 2017;15:520-37. [PMID: 28852967 DOI: 10.1007/s11938-017-0150-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
55 Bernards N, Haj Mohammad N, Creemers GJ, de Hingh IH, van Laarhoven HW, Lemmens VE. Ten weeks to live: a population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands. Acta Oncol 2015;54:403-10. [PMID: 25263080 DOI: 10.3109/0284186X.2014.953257] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
56 Ye J, Mills BN, Zhao T, Han BJ, Murphy JD, Patel AP, Johnston CJ, Lord EM, Belt BA, Linehan DC, Gerber SA. Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer. Cancer Immunol Res 2020;8:94-107. [PMID: 31719057 DOI: 10.1158/2326-6066.CIR-19-0373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
57 Imai K, Margonis GA, Wang J, Wolfgang CL, Baba H, Weiss MJ. Liver metastases from pancreatic ductal adenocarcinoma: is there a place for surgery in the modern era? Journal of Pancreatology 2020;3:81-5. [DOI: 10.1097/jp9.0000000000000042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Tekin C, Shi K, Daalhuisen JB, Ten Brink MS, Bijlsma MF, Spek CA. PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer. Oncotarget 2018;9:32010-23. [PMID: 30174793 DOI: 10.18632/oncotarget.25880] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
59 Assenat E, de la Fouchardière C, Portales F, Ychou M, Debourdeau A, Desseigne F, Iltache S, Fiess C, Mollevi C, Mazard T. Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial. ESMO Open 2021;6:100318. [PMID: 34837745 DOI: 10.1016/j.esmoop.2021.100318] [Reference Citation Analysis]
60 Wysocka O, Kulbacka J, Saczko J. Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. Prz Gastroenterol 2016;11:155-62. [PMID: 27713776 DOI: 10.5114/pg.2016.61438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
61 Kobayashi S, Ueno M, Irie K, Goda Y, Aoyama T, Morinaga S, Ohkawa S, Morimoto M. Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma. Pancreatology 2015;15:525-30. [PMID: 26255025 DOI: 10.1016/j.pan.2015.07.003] [Reference Citation Analysis]
62 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
63 Schlick K, Kiem D, Huemer F, Neureiter D, Weiss L, Greil R. Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. Technol Cancer Res Treat 2021;20:15330338211042139. [PMID: 34595977 DOI: 10.1177/15330338211042139] [Reference Citation Analysis]
64 O'Reilly EM. Early Detection and Treatment Opportunities in Pancreatic Adenocarcinoma. J Oncol Pract 2016;12:31-2. [PMID: 26759463 DOI: 10.1200/JOP.2015.009985] [Reference Citation Analysis]
65 Takano H, Nakamura T, Tsuchikawa T, Kushibiki T, Hontani K, Inoko K, Takahashi M, Sato S, Abe H, Takeuchi S, Sato N, Hiraoka K, Nishihara H, Shichinohe T, Hirano S. Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. Oncotarget 2015;6:41063-76. [PMID: 26516928 DOI: 10.18632/oncotarget.5729] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
66 Oziel-Taieb S, Faure M, Gilabert M, Autret A, Turrini O, Moureau-Zabotto L, Giovannini M, Rousseau F, Raoul JL. Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. J Gastrointest Cancer 2016;47:15-9. [PMID: 26545612 DOI: 10.1007/s12029-015-9774-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
67 Bullock A, Stuart K, Jacobus S, Abrams T, Wadlow R, Goldstein M, Miksad R. Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma.J Gastrointest Oncol. 2017;8:945-952. [PMID: 29299353 DOI: 10.21037/jgo.2017.06.06] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
68 Fanchon LM, Russell J, Pillarsetty N, O'Donoghue I, Gangangari K, Yu KH, Humm JL. Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma. PLoS One 2020;15:e0231745. [PMID: 32298392 DOI: 10.1371/journal.pone.0231745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
69 Cloyd JM, Katz MHG, Wang H, Cuddy A, You YN. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma. JAMA Surg 2017;152:1086-8. [PMID: 28793134 DOI: 10.1001/jamasurg.2017.2631] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
70 Carrasco-garcia E, Lopez L, Moncho-amor V, Carazo F, Aldaz P, Collado M, Bell D, Gaafar A, Karamitopoulou E, Tzankov A, Hidalgo M, Rubio Á, Serrano M, Lawrie CH, Lovell-badge R, Matheu A. SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression. Cancers 2022;14:916. [DOI: 10.3390/cancers14040916] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Decoster C, Gilabert M, Autret A, Turrini O, Oziel-Taieb S, Poizat F, Giovannini M, Viens P, Iovanna J, Raoul JL. Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study. Oncotarget 2016;7:45649-55. [PMID: 27286454 DOI: 10.18632/oncotarget.9861] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
72 Lao M, Zhang X, Ma T, Xu J, Yang H, Duan Y, Ying H, Zhang X, Guo C, Qiu J, Bai X, Liang T. Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. Oncogene 2021;40:3136-51. [PMID: 33824473 DOI: 10.1038/s41388-021-01763-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Marchetti C, Zyner KG, Ohnmacht SA, Robson M, Haider SM, Morton JP, Marsico G, Vo T, Laughlin-Toth S, Ahmed AA, Di Vita G, Pazitna I, Gunaratnam M, Besser RJ, Andrade ACG, Diocou S, Pike JA, Tannahill D, Pedley RB, Evans TRJ, Wilson WD, Balasubramanian S, Neidle S. Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule. J Med Chem 2018;61:2500-17. [PMID: 29356532 DOI: 10.1021/acs.jmedchem.7b01781] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 15.5] [Reference Citation Analysis]
74 Suzuki N, Hazama S, Ueno T, Matsui H, Shindo Y, Iida M, Yoshimura K, Yoshino S, Takeda K, Oka M. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. J Immunother 2014;37:36-42. [PMID: 24316554 DOI: 10.1097/CJI.0000000000000012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
75 O'Reilly EM, Park W, Kelsen DP. Reply to N. Fazio.J Clin Oncol. 2020;38:2467-2468. [PMID: 32407214 DOI: 10.1200/JCO.20.00833] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Andrianello S, Marchegiani G, Salvia R. ASO Author Reflections: Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer. Ann Surg Oncol 2018;25:810-1. [PMID: 30374921 DOI: 10.1245/s10434-018-6874-y] [Reference Citation Analysis]
77 Suzuki R, Takagi T, Hikichi T, Sugimoto M, Konno N, Asama H, Watanabe K, Nakamura J, Marubashi S, Ohira H. An observation study of the prognostic effect of waiting times in the management of pancreatic ductal adenocarcinoma. Oncol Lett 2019;17:587-93. [PMID: 30655805 DOI: 10.3892/ol.2018.9626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
78 Mesmar F, Dai B, Ibrahim A, Hases L, Jafferali MH, Jose Augustine J, DiLorenzo S, Kang Y, Zhao Y, Wang J, Kim M, Lin CY, Berkenstam A, Fleming J, Williams C. Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling. Cancer Med 2019;8:7705-19. [PMID: 31568691 DOI: 10.1002/cam4.2581] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
79 Flammang I, Reese M, Yang Z, Eble JA, Dhayat SA. Tumor-Suppressive miR-192-5p Has Prognostic Value in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2020;12:E1693. [PMID: 32630552 DOI: 10.3390/cancers12061693] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
80 Reni M. APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma. Lancet Oncol 2021;22:10-1. [PMID: 33387488 DOI: 10.1016/S1470-2045(20)30724-5] [Reference Citation Analysis]
81 Suzuki R, Takagi T, Hikichi T, Konno N, Sugimoto M, Watanabe KO, Nakamura J, Waragai Y, Kikuchi H, Takasumi M, Watanabe H, Ohira H. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncol Lett 2016;11:3441-5. [PMID: 27123132 DOI: 10.3892/ol.2016.4381] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
82 Kim M, Mun JG, Lee HJ, Son SR, Lee MJ, Kee JY. Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells. Molecules 2019;24:E3829. [PMID: 31652886 DOI: 10.3390/molecules24213829] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
83 Yang SH, Lu LC, Kao HF, Chen BB, Kuo TC, Kuo SH, Tien YW, Bai LY, Cheng AL, Yeh KH. Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. Oncoimmunology 2021;10:1973710. [PMID: 34595057 DOI: 10.1080/2162402X.2021.1973710] [Reference Citation Analysis]
84 Gillson J, Abd El-aziz YS, Leck LYW, Jansson PJ, Pavlakis N, Samra JS, Mittal A, Sahni S. Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target. Cancers 2022;14:3528. [DOI: 10.3390/cancers14143528] [Reference Citation Analysis]
85 Siolas D, Morrissey C, Oberstein PE. The Achilles' Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials. J Pancreatol 2020;3:121-31. [PMID: 33133736 DOI: 10.1097/JP9.0000000000000052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Mizrahi JD, Rogers JE, Hess KR, Wolff RA, Varadhachary GR, Javle MM, Shroff RT, Ho L, Fogelman DR, Raghav KPS, Overman MJ, Pant S. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology 2020;20:501-4. [PMID: 31932214 DOI: 10.1016/j.pan.2020.01.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
87 Hwang AL, Haynes K, Hwang WT, Yang YX. Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas. 2013;42:1054-1059. [PMID: 24051965 DOI: 10.1097/mpa.0b013e3182965a3c] [Cited by in Crossref: 46] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
88 Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr Oncol Rep. 2013;15:182-189. [PMID: 23341367 DOI: 10.1007/s11912-012-0290-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
89 Zhao J, Zhao F, Shi Y, Deng Y, Hu X, Shen H. The efficacy of a new high intensity focused ultrasound therapy for locally advanced pancreatic cancer. J Cancer Res Clin Oncol 2017;143:2105-11. [PMID: 28620685 DOI: 10.1007/s00432-017-2459-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
90 Wang X, Zhang CS, Dong XY, Hu Y, Duan BJ, Bai J, Wu YY, Fan L, Liao XH, Kang Y, Zhang P, Li MY, Xu J, Mao ZJ, Liu HT, Zhang XL, Tian LF, Li EX. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2022; 14(7): 1252-1264 [DOI: 10.4251/wjgo.v14.i7.1252] [Reference Citation Analysis]
91 Awasthi N, Monahan S, Stefaniak A, Schwarz MA, Schwarz RE. Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. Oncotarget 2018;9:5274-86. [PMID: 29435178 DOI: 10.18632/oncotarget.23684] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
92 Bruera G, Massacese S, Candria S, Galvano A, Manetta R, Giordano AV, Carducci S, Di Sibio A, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy. Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget 2018;9:31861-76. [PMID: 30159128 DOI: 10.18632/oncotarget.25870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
93 Pu N, Chen Q, Yin H, Zhang J, Zhao G, Habib JR, Chen J, Yu J, Lou W, Wu W. Identification of an Immune-Related BAT Signature for Predicting Adjuvant Chemotherapy Response and Overall Survival in Patients with Resected Ductal Adenocarcinoma of the Pancreas. J Gastrointest Surg. [DOI: 10.1007/s11605-021-05232-6] [Reference Citation Analysis]
94 Fiorentini G, Sarti D, Casadei V, Milandri C, Dentico P, Mambrini A, Nani R, Fiorentini C, Guadagni S. Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients.Integr Cancer Ther. 2019;18:1534735419878505. [PMID: 31561722 DOI: 10.1177/1534735419878505] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
95 LaRocca CJ, Warner SG. A New Role for Vitamin D: The Enhancement of Oncolytic Viral Therapy in Pancreatic Cancer. Biomedicines 2018;6:E104. [PMID: 30400571 DOI: 10.3390/biomedicines6040104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
96 Torres MP, Rachagani S, Souchek JJ, Mallya K, Johansson SL, Batra SK. Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy. PLoS One 2013;8:e80580. [PMID: 24278292 DOI: 10.1371/journal.pone.0080580] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 7.6] [Reference Citation Analysis]
97 Hu X, Xiao Y, Sun J, Ji B, Luo S, Wu B, Zheng C, Wang P, Xu F, Cheng K, Hua H, Li D. New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors. Acta Pharm Sin B 2021;11:1148-57. [PMID: 34094825 DOI: 10.1016/j.apsb.2020.10.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
98 Chen Q, Wang J, Zhang Q, Zhang J, Lou Y, Yang J, Chen Y, Wei T, Zhang J, Fu Q, Ye M, Zhang X, Dang X, Liang T, Bai X. Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. Br J Cancer. 2019;121:786-795. [PMID: 31588122 DOI: 10.1038/s41416-019-0595-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
99 Buc E, Orry D, Antomarchi O, Gagnière J, Da Ines D, Pezet D. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile? World J Surg Oncol 2014;12:347. [PMID: 25407113 DOI: 10.1186/1477-7819-12-347] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
100 Peng H, Chen R, Brentnall TA, Eng JK, Picozzi VJ, Pan S. Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy. Clin Proteomics. 2019;16:31. [PMID: 31346328 DOI: 10.1186/s12014-019-9251-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
101 Mohammed A, Janakiram NB, Pant S, Rao CV. Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel) 2015;7:1499-542. [PMID: 26266422 DOI: 10.3390/cancers7030850] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
102 Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Mol Ther Oncolytics 2019;12:56-67. [PMID: 30705966 DOI: 10.1016/j.omto.2018.12.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
103 Nishimoto A. Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. World J Gastroenterol 2022; 28(28): 3637-3643 [DOI: 10.3748/wjg.v28.i28.3637] [Reference Citation Analysis]
104 Ge L, Pan B, Song F, Ma J, Zeraatkar D, Zhou J, Tian J. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. BMJ Open 2017;7:e018175. [PMID: 29282264 DOI: 10.1136/bmjopen-2017-018175] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
105 Iwai N, Okuda T, Sakagami J, Harada T, Ohara T, Taniguchi M, Sakai H, Oka K, Hara T, Tsuji T, Komaki T, Kagawa K, Yasuda H, Naito Y, Itoh Y. Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer. Sci Rep 2020;10:18758. [PMID: 33127996 DOI: 10.1038/s41598-020-75745-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
106 Kudo Y, Sato N, Tamura T, Hirata K. Triple bypass for advanced pancreatic head cancer associated with biliary stricture, duodenal stenosis, and recurrent obstructive pancreatitis. Surg Case Rep 2016;2:79. [PMID: 27495991 DOI: 10.1186/s40792-016-0210-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
107 Calvo F, Guillen Ponce C, Muñoz Beltran M, Sanjuanbenito Dehesa A. Multidisciplinary management of locally advanced–borderline resectable adenocarcinoma of the head of the pancreas. Clin Transl Oncol 2013;15:173-81. [DOI: 10.1007/s12094-012-0962-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
108 Dorman K, Gerckens M, Kruger S, Krueger K, Mayer Z, Rupp A, Zhang D, Weiss L, Westphalen CB, Haas M, Guenther M, Ormanns S, Klawonn F, Werner J, von Bergwelt-Baildon M, Heinemann V, Boeck S, Holdenrieder S. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers. J Cancer Res Clin Oncol 2022. [PMID: 35737090 DOI: 10.1007/s00432-022-04112-z] [Reference Citation Analysis]
109 Fernandes GDS, Pereira A. Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? ESMO Open 2019;4:e000537. [PMID: 31354965 DOI: 10.1136/esmoopen-2019-000537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
110 Gu J, Xu Z, Ma Y, Chen H, Wang D, Deng X, Cheng D, Xie J, Jin J, Zhan X, Shi Y, Shi Y, Zhu Y, Shen B, Peng C. Surgical resection of metastatic pancreatic cancer: is it worth it?-a 15-year experience at a single Chinese center. J Gastrointest Oncol 2020;11:319-28. [PMID: 32399273 DOI: 10.21037/jgo.2020.03.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
111 Rocha FG. Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer. Ann Surg Oncol 2021;28:1400-6. [PMID: 33386541 DOI: 10.1245/s10434-020-09367-9] [Reference Citation Analysis]
112 Tehfe M, Dowden S, Kennecke H, El-Maraghi R, Lesperance B, Couture F, Letourneau R, Liu H, Romano A. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Adv Ther 2016;33:747-59. [PMID: 27085323 DOI: 10.1007/s12325-016-0327-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
113 Iwamoto H, Izumi K, Mizokami A. Is the C-C Motif Ligand 2-C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis? Int J Mol Sci 2020;21:E9328. [PMID: 33297571 DOI: 10.3390/ijms21239328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
114 Hendifar A, Blais EM, Wolpin B, Subbiah V, Collisson E, Singh I, Cannon T, Shaw K, Petricoin EF 3rd, Klempner S, Lyons E, Wang-Gillam A, Pishvaian MJ, O'Reilly EM. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precis Oncol 2021;5:PO. [PMID: 34476331 DOI: 10.1200/PO.20.00494] [Reference Citation Analysis]
115 Kruger S, Legenstein ML, Rösgen V, Haas M, Modest DP, Westphalen CB, Ormanns S, Kirchner T, Heinemann V, Holdenrieder S, Boeck S. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology 2017;6:e1310358. [PMID: 28638732 DOI: 10.1080/2162402X.2017.1310358] [Cited by in Crossref: 59] [Cited by in F6Publishing: 42] [Article Influence: 11.8] [Reference Citation Analysis]
116 Imamura T, Ohgi K, Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Otsuka S, Tamura S, Uesaka K. The clinical benefits of performing staging laparoscopy for pancreatic cancer treatment. Pancreatology 2022. [DOI: 10.1016/j.pan.2022.03.017] [Reference Citation Analysis]
117 Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C. Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting. Cancer Manag Res 2017;9:141-8. [PMID: 28461766 DOI: 10.2147/CMAR.S126073] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
118 de la Fouchardière C, Gamradt P, Chabaud S, Raddaz M, Blanc E, Msika O, Treilleux I, Bachy S, Cattey-javouhey A, Guibert P, Sarabi M, Rochefort P, Funk-debleds P, Coutzac C, Ray-coquard I, Peyrat P, Meeus P, Rivoire M, Dupré A, Hennino A. A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3. JPM 2022;12:623. [DOI: 10.3390/jpm12040623] [Reference Citation Analysis]
119 Vreeland TJ, McAllister F, Javadi S, Prakash LR, Fogelman DR, Ho L, Varadhachary G, Aloia TA, Vauthey JN, Lee JE, Kim MP, Katz MHG, Tzeng CD. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. Pancreas 2019;48:837-43. [PMID: 31210666 DOI: 10.1097/MPA.0000000000001345] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
120 Yildirim ÖA, Erdur E. Pancreatic cancer treatment after FOLFIRINOX: prognostic importance of chemotherapy dose intensity and albumin/globulin ratio in second line. Journal of Health Sciences and Medicine 2022;5:156-60. [DOI: 10.32322/jhsm.1011658] [Reference Citation Analysis]
121 Hakim N, Patel R, Devoe C, Saif MW. Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. Pancreas (Fairfax) 2019;3:e1-4. [PMID: 32030361 DOI: 10.17140/POJ-3-e010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
122 Lundy J, Gearing LJ, Gao H, West AC, McLeod L, Deswaerte V, Yu L, Porazinski S, Pajic M, Hertzog PJ, Croagh D, Jenkins BJ. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma. Oncogene 2021. [PMID: 34400766 DOI: 10.1038/s41388-021-01992-2] [Reference Citation Analysis]
123 Ding J, Li H, Liu Y, Xie Y, Yu J, Sun H, Xiao D, Zhou Y, Bao L, Wang H, Gao C. OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:698302. [PMID: 34804914 DOI: 10.3389/fonc.2021.698302] [Reference Citation Analysis]
124 Broadhurst PJ, Hart AR. Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use. Dig Dis Sci. 2018;63:2840-2852. [PMID: 30159732 DOI: 10.1007/s10620-018-5233-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
125 Ozmen F, Şahin TT, Ozmen MM. Current adjuvant therapeutic approaches for pancreatic cancer. Adv Ther 2015;32:42-56. [PMID: 25595483 DOI: 10.1007/s12325-015-0177-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
126 Huang J, Qian W, Wang L, Wu H, Zhou H, Wang AY, Chen H, Yang L, Mao H. Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer. Int J Nanomedicine 2016;11:3087-99. [PMID: 27462153 DOI: 10.2147/IJN.S92722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
127 Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res. 2015;3:399-411. [PMID: 25678581 DOI: 10.1158/2326-6066.cir-14-0215] [Cited by in Crossref: 242] [Cited by in F6Publishing: 171] [Article Influence: 34.6] [Reference Citation Analysis]
128 Scheithauer W, Putora PM, Grünberger B, Eisterer W, Wöll E, Prager G, Schaberl-Moser R, Greil R, Glatzer M. Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. Therap Adv Gastroenterol 2019;12:1756284819877635. [PMID: 31579123 DOI: 10.1177/1756284819877635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Huang P, Zhong XY, Xu Y, Cui YF. Role of neoadjuvant therapy and adjuvant therapy in treatment of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(14): 1292-1296 [DOI: 10.11569/wcjd.v21.i14.1292] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Mezencev R, Matyunina LV, Wagner GT, McDonald JF. Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes. Cancer Gene Ther 2016;23:446-53. [PMID: 27910856 DOI: 10.1038/cgt.2016.71] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
131 Park W, Chawla A, O'Reilly EM. Pancreatic Cancer: A Review. JAMA 2021;326:851-62. [PMID: 34547082 DOI: 10.1001/jama.2021.13027] [Cited by in Crossref: 57] [Cited by in F6Publishing: 30] [Article Influence: 57.0] [Reference Citation Analysis]
132 Flick KF, Al-Temimi MH, Maatman TK, Sublette CM, Swensson JK, Nakeeb A, Ceppa EP, Nguyen TK, Schmidt CM, Zyromski NJ, Tann MA, House MG. Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy. J Gastrointest Surg 2020;24:2008-14. [PMID: 32671796 DOI: 10.1007/s11605-020-04723-2] [Reference Citation Analysis]
133 Apostolidis L, Schwarz D, Xia A, Weiler M, Heckel A, Godel T, Heiland S, Schlemmer HP, Jäger D, Bendszus M, Bäumer P. Dorsal root ganglia hypertrophy as in vivo correlate of oxaliplatin-induced polyneuropathy. PLoS One 2017;12:e0183845. [PMID: 28837658 DOI: 10.1371/journal.pone.0183845] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
134 Hong S, Kim KW, Park HJ, Ko Y, Yoo C, Park SY, Khang S, Jeong H, Lee J. Impact of Baseline Muscle Mass and Myosteatosis on the Development of Early Toxicity During First-Line Chemotherapy in Patients With Initially Metastatic Pancreatic Cancer. Front Oncol 2022;12:878472. [DOI: 10.3389/fonc.2022.878472] [Reference Citation Analysis]
135 Koutsounas I, Giaginis C, Patsouris E, Theocharis S. Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J Gastroenterol 2013; 19(6): 813-828 [PMID: 23430136 DOI: 10.3748/wjg.v19.i6.813] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
136 Barbieri A, Peyhardi J, Conroy T, Gourgou S, Lavergne C, Mollevi C. Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials. BMC Med Res Methodol 2017;17:148. [PMID: 28950850 DOI: 10.1186/s12874-017-0410-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
137 Wang Z, Ren ZG, Ma NY, Zhao JD, Zhang Z, Ma XJ, Long J, Xu J, Jiang GL. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis. Radiat Oncol 2015;10:14. [PMID: 25575617 DOI: 10.1186/s13014-014-0312-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
138 Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci 2019;20:E4543. [PMID: 31540286 DOI: 10.3390/ijms20184543] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
139 Hsueh CT, Selim JH, Tsai JY, Hsueh CT. Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(31): 7080-7090 [PMID: 27610018 DOI: 10.3748/wjg.v22.i31.7080] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
140 Yoo C, Im HS, Kim KP, Oh DY, Lee KH, Chon HJ, Kim JH, Kang M, Kim I, Lee GJ, Oh SY, Choi Y, Choi HJ, Kim ST, Park JO, Ryoo BY. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/Leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Ther Adv Med Oncol. 2019;11:1758835919871126. [PMID: 31489036 DOI: 10.1177/1758835919871126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
141 Shrikhande SV, Barreto SG. Surgery for pancreatic carcinoma: state of the art. Indian J Surg. 2012;74:79-86. [PMID: 23372311 DOI: 10.1007/s12262-011-0373-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
142 Singh D, Dheer D, Samykutty A, Shankar R. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. J Control Release 2021;340:1-34. [PMID: 34673122 DOI: 10.1016/j.jconrel.2021.10.006] [Reference Citation Analysis]
143 Akahori T, Sho M, Yanagimoto H, Satoi S, Nagai M, Nishiwada S, Nakagawa K, Nakamura K, Yamamoto T, Hirooka S, Yamaki S, Ikeda N. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Oncologist. 2019;. [PMID: 30679316 DOI: 10.1634/theoncologist.2018-0900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
144 Del Re M, Vivaldi C, Rofi E, Salani F, Crucitta S, Catanese S, Fontanelli L, Massa V, Cucchiara F, Fornaro L, Capuano A, Fogli S, Vasile E, Danesi R. Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. Cancers (Basel) 2021;13:3738. [PMID: 34359638 DOI: 10.3390/cancers13153738] [Reference Citation Analysis]
145 Razidlo GL, Magnine C, Sletten AC, Hurley RM, Almada LL, Fernandez-Zapico ME, Ji B, McNiven MA. Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion. Cancer Res. 2015;75:2907-2915. [PMID: 25977335 DOI: 10.1158/0008-5472.can-14-3103] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
146 Rashid NU, Peng XL, Jin C, Moffitt RA, Volmar KE, Belt BA, Panni RZ, Nywening TM, Herrera SG, Moore KJ, Hennessey SG, Morrison AB, Kawalerski R, Nayyar A, Chang AE, Schmidt B, Kim HJ, Linehan DC, Yeh JJ. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Clin Cancer Res 2020;26:82-92. [PMID: 31754050 DOI: 10.1158/1078-0432.CCR-19-1467] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
147 Shin SW, Jung W, Choi C, Kim SY, Son A, Kim H, Lee N, Park HC. Fucoidan-Manganese Dioxide Nanoparticles Potentiate Radiation Therapy by Co-Targeting Tumor Hypoxia and Angiogenesis. Mar Drugs 2018;16:E510. [PMID: 30558324 DOI: 10.3390/md16120510] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
148 Fenocchio E, Filippi R, Lombardi P, Quarà V, Milanesio M, Aimar G, Leone F, Aglietta M. Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? Cancers (Basel) 2019;11:E1547. [PMID: 31614884 DOI: 10.3390/cancers11101547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
149 Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017;152:1048-1056. [PMID: 28700784 DOI: 10.1001/jamasurg.2017.2227] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 11.0] [Reference Citation Analysis]
150 Bian Y, Liu YF, Jiang H, Meng Y, Liu F, Cao K, Zhang H, Fang X, Li J, Yu J, Feng X, Li Q, Wang L, Lu J, Shao C. Machine learning for MRI radiomics: a study predicting tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma. Abdom Radiol (NY) 2021;46:4800-16. [PMID: 34189612 DOI: 10.1007/s00261-021-03159-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Tiwari A, Kumar L. Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives. Indian J Med Res 2018;148:254-7. [PMID: 30425214 DOI: 10.4103/ijmr.IJMR_615_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Fan X, Zhang X, Shen J, Zhao H, Yu X, Chen Y, Zhuang Z, Deng X, Feng H, Wang Y, Peng L. Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis. PLoS One 2016;11:e0149028. [PMID: 26871953 DOI: 10.1371/journal.pone.0149028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
153 Tran NH, Sahai V, Griffith KA, Nathan H, Kaza R, Cuneo KC, Shi J, Kim E, Sonnenday CJ, Cho CS, Lawrence TS, Zalupski MM. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2020;106:124-33. [PMID: 31494181 DOI: 10.1016/j.ijrobp.2019.08.057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
154 Sarabi M, Mais L, Oussaid N, Desseigne F, Guibert P, De La Fouchardiere C. Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncol Lett. 2017;13:4917-4924. [PMID: 28599496 DOI: 10.3892/ol.2017.6061] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
155 Kipps E, Young K, Starling N. Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. Ther Adv Med Oncol 2017;9:159-70. [PMID: 28344661 DOI: 10.1177/1758834016688816] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
156 Leonhardt CS, Traub B, Hackert T, Klaiber U, Strobel O, Büchler MW, Neoptolemos JP. Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. Journal of Pancreatology 2020;3:1-11. [DOI: 10.1097/jp9.0000000000000040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
157 Whittle MC, Hingorani SR. Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems. Cancer J 2017;23:326-32. [PMID: 29189328 DOI: 10.1097/PPO.0000000000000289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Takahashi R, Ijichi H, Sano M, Miyabayashi K, Mohri D, Kim J, Kimura G, Nakatsuka T, Fujiwara H, Yamamoto K, Kudo Y, Tanaka Y, Tateishi K, Nakai Y, Morishita Y, Soma K, Takeda N, Moses HL, Isayama H, Koike K. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Sci Rep 2020;10:21194. [PMID: 33273652 DOI: 10.1038/s41598-020-78320-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
159 Ueno M, Li CP, Ikeda M, Ishii H, Mizuno N, Yamaguchi T, Ioka T, Oh DY, Ichikawa W, Okusaka T, Matsuyama Y, Arai D, Chen LT, Park YS, Furuse J. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. Cancer Chemother Pharmacol 2017;80:307-15. [PMID: 28634650 DOI: 10.1007/s00280-017-3351-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
160 Duan Z, Chinn D, Tu MJ, Zhang QY, Huynh J, Chen J, Mack P, Yu AM, Kim EJ. Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. Transl Oncol 2019;12:683-92. [PMID: 30844579 DOI: 10.1016/j.tranon.2019.01.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
161 Kelly CM, Shahrokni A. Moving beyond Karnofsky and ECOG Performance Status Assessments with New Technologies. J Oncol 2016;2016:6186543. [PMID: 27066075 DOI: 10.1155/2016/6186543] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 13.5] [Reference Citation Analysis]
162 Yoo C, Shin SH, Kim KP, Jeong JH, Chang HM, Kang JH, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Hwang DW, Song KB, Lee JH, Ryoo BY, Kim SC. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis. Cancers (Basel). 2019;11. [PMID: 30813624 DOI: 10.3390/cancers11030278] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
163 de Jesus VHF, Camandaroba MPG, Calsavara VF, Riechelmann RP. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer.Ther Adv Med Oncol. 2020;12:1758835920905408. [PMID: 32165927 DOI: 10.1177/1758835920905408] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
164 Amin S, Baine M, Meza J, Alam M, Lin C. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. Clin Transl Radiat Oncol 2020;24:34-40. [PMID: 32613090 DOI: 10.1016/j.ctro.2020.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
165 Narayanan V, Weekes CD. Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol 2016; 8(4): 366-379 [PMID: 27096032 DOI: 10.4251/wjgo.v8.i4.366] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
166 Chevalier H, Vienot A, Lièvre A, Edeline J, El Hajbi F, Peugniez C, Vernerey D, Meurisse A, Hammel P, Neuzillet C, Borg C, Turpin A. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.Oncologist. 2020;25:e1701-e1710. [PMID: 32886823 DOI: 10.1634/theoncologist.2020-0577] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
167 Gibbs P, Do C, Lipton L, Cade DN, Tapner MJ, Price D, Bower GD, Dowling R, Lichtenstein M, van Hazel GA. Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma. BMC Cancer 2015;15:802. [PMID: 26503593 DOI: 10.1186/s12885-015-1822-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
168 Zechner D, Bürtin F, Amme J, Lindner T, Radecke T, Hadlich S, Kühn JP, Vollmar B. Characterization of novel carcinoma cell lines for the analysis of therapeutical strategies fighting pancreatic cancer. Cell Biosci 2015;5:51. [PMID: 26322225 DOI: 10.1186/s13578-015-0038-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
169 Broekgaarden M, Anbil S, Bulin AL, Obaid G, Mai Z, Baglo Y, Rizvi I, Hasan T. Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D culture platform of pancreatic cancer. Biomaterials 2019;222:119421. [PMID: 31494503 DOI: 10.1016/j.biomaterials.2019.119421] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
170 O'Kane GM, Lowery MA. Moving the Needle on Precision Medicine in Pancreatic Cancer. J Clin Oncol 2022;:JCO2102514. [PMID: 35839440 DOI: 10.1200/JCO.21.02514] [Reference Citation Analysis]
171 Raschzok N, Stintzing S, Heinemann V, Rauch G, Ricke J, Guckenberger M, Kurreck A, Alig AHS, Stahler A, Bullinger L, Schmelzle M, Schöning W, Lurje G, Krenzien F, Haase O, Rau B, Gebauer B, Sauer IM, Pratschke J, Modest DP. FIRE-9 – PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09422-6] [Reference Citation Analysis]
172 Shi Z, Yang J, Kong W, Qiu X, Lu C, Liu J, Liu B, Du J. Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer. Front Oncol 2022;12:782730. [PMID: 35299738 DOI: 10.3389/fonc.2022.782730] [Reference Citation Analysis]
173 Liu X, Jiang J, Liao YP, Tang I, Zheng E, Qiu W, Lin M, Wang X, Ji Y, Mei KC, Liu Q, Chang CH, Wainberg ZA, Nel AE, Meng H. Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. Adv Sci (Weinh) 2021;8:2002147. [PMID: 33747719 DOI: 10.1002/advs.202002147] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
174 Ay S, Atcı MM, Arıkan R, Dülgar Ö, Özyükseler DT, Paksoy N, Doğan İ, Öztosun B, Taştekin D, Öven BB, Gümüş M. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. J Chemother 2022;:1-7. [PMID: 35037592 DOI: 10.1080/1120009X.2022.2026125] [Reference Citation Analysis]
175 Pusceddu S, Ghidini M, Torchio M, Corti F, Tomasello G, Niger M, Prinzi N, Nichetti F, Coinu A, Di Bartolomeo M, Cabiddu M, Passalacqua R, de Braud F, Petrelli F. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 30959763 DOI: 10.3390/cancers11040484] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
176 Xin X, Kumar V, Lin F, Kumar V, Bhattarai R, Bhatt VR, Tan C, Mahato RI. Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy. Sci Adv 2020;6:eabd6764. [PMID: 33177098 DOI: 10.1126/sciadv.abd6764] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
177 Aiello NM, Bajor DL, Norgard RJ, Sahmoud A, Bhagwat N, Pham MN, Cornish TC, Iacobuzio-Donahue CA, Vonderheide RH, Stanger BZ. Metastatic progression is associated with dynamic changes in the local microenvironment. Nat Commun 2016;7:12819. [PMID: 27628423 DOI: 10.1038/ncomms12819] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 11.8] [Reference Citation Analysis]
178 Sohn BS, Yuh YJ, Song HS, Kim BS, Lee KH, Jang JS, Kim SR. Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer. Oncol Lett 2015;10:1204-10. [PMID: 26622653 DOI: 10.3892/ol.2015.3347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
179 Ota S, Miyashita M, Yamagishi Y, Ogasawara M. Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy. Hum Vaccin Immunother 2021;:1-10. [PMID: 34919493 DOI: 10.1080/21645515.2021.2003645] [Reference Citation Analysis]
180 Hang J, Xue P, Yang H, Li S, Chen D, Zhu L, Huang W, Ren S, Zhu Y, Wang L. Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Sci Rep 2017;7:2993. [PMID: 28592881 DOI: 10.1038/s41598-017-03153-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
181 Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2:260-269. [PMID: 22585996 DOI: 10.1158/2159-8290.cd-11-0242] [Cited by in Crossref: 261] [Cited by in F6Publishing: 151] [Article Influence: 26.1] [Reference Citation Analysis]
182 Olson P, Chu GC, Perry SR, Nolan-Stevaux O, Hanahan D. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci USA. 2011;108:E1275-E1284. [PMID: 22084065 DOI: 10.1073/pnas.1111079108] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
183 Soni KS, Thomas D, Caffrey T, Mehla K, Lei F, O'Connell KA, Sagar S, Lele SM, Hollingsworth MA, Radhakrishnan P, Bronich TK. A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer. J Pharmacol Exp Ther 2019;370:894-901. [PMID: 30683666 DOI: 10.1124/jpet.118.255372] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
184 Orlandi A, Calegari MA, Martini M, Cocomazzi A, Bagalà C, Indellicati G, Zurlo V, Basso M, Cassano A, Larocca LM, Barone C. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. Clin Transl Oncol 2016;18:988-95. [PMID: 26742940 DOI: 10.1007/s12094-015-1471-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
185 O'Kane GM, Ladak F, Gallinger S. Advances in the management of pancreatic ductal adenocarcinoma. CMAJ 2021;193:E844-51. [PMID: 34099468 DOI: 10.1503/cmaj.201450] [Reference Citation Analysis]
186 Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801-810. [PMID: 27160474 DOI: 10.1016/s1470-2045(16)00172-8] [Cited by in Crossref: 416] [Cited by in F6Publishing: 193] [Article Influence: 69.3] [Reference Citation Analysis]
187 Oyasiji T, Ma WW. Novel adjuvant therapies for pancreatic adenocarcinoma. J Gastrointest Oncol 2015;6:430-5. [PMID: 26261729 DOI: 10.3978/j.issn.2078-6891.2015.031] [Reference Citation Analysis]
188 Haas M, Heinemann V, Kullmann F, Laubender RP, Klose C, Bruns CJ, Holdenrieder S, Modest DP, Schulz C, Boeck S. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139:681-689. [PMID: 23315099 DOI: 10.1007/s00432-012-1371-3] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 9.9] [Reference Citation Analysis]
189 Li L, Tang W, Wu X, Karnak D, Meng X, Thompson R, Hao X, Li Y, Qiao XT, Lin J. HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s. Clin Cancer Res. 2013;19:6703-6715. [PMID: 24132924 DOI: 10.1158/1078-0432.ccr-13-0621] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
190 Zhang Q, Rui W, Jiang Y, Yuan F, Chen Y, Guo X, Zhou Y, Wu Z, Wang C, Ding X. Tumor-infiltrating OX40+ lymphocytes is an independent positive prognostic factor for patients with pancreatic ductal adenocarcinoma. Clin Transl Oncol 2022. [PMID: 35731350 DOI: 10.1007/s12094-022-02864-1] [Reference Citation Analysis]
191 Shimasaki T, Kitano A, Motoo Y, Minamoto T. Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. J Carcinog 2012;11:15. [PMID: 23230392 DOI: 10.4103/1477-3163.100866] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
192 Chen X, An Y, Zhang Y, Xu D, Chen T, Yang Y, Chen W, Wu D, Zhang X. CCL26 is upregulated by nab-paclitaxel in pancreatic cancer-associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K/AKT/mTOR pathway. Acta Biochim Biophys Sin (Shanghai) 2021;53:612-9. [PMID: 33764366 DOI: 10.1093/abbs/gmab032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
193 Lytle NK, Ferguson LP, Rajbhandari N, Gilroy K, Fox RG, Deshpande A, Schürch CM, Hamilton M, Robertson N, Lin W, Noel P, Wartenberg M, Zlobec I, Eichmann M, Galván JA, Karamitopoulou E, Gilderman T, Esparza LA, Shima Y, Spahn P, French R, Lewis NE, Fisch KM, Sasik R, Rosenthal SB, Kritzik M, Von Hoff D, Han H, Ideker T, Deshpande AJ, Lowy AM, Adams PD, Reya T. A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. Cell 2019;177:572-586.e22. [PMID: 30955884 DOI: 10.1016/j.cell.2019.03.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 13.7] [Reference Citation Analysis]
194 Yun W, Kwon W, Han Y, Sohn HJ, Kim HS, Lee M, Kim H, Thomas AS, Kluger MD, Jang J. Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis? Cancers 2022;14:2067. [DOI: 10.3390/cancers14092067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Catanese S, Pentheroudakis G, Douillard JY, Lordick F. ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. ESMO Open. 2020;5. [PMID: 32423899 DOI: 10.1136/esmoopen-2020-000804] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
196 Chitwood H, Hampton D, Patel R. The effect of amino acid-oral rehydration solution (Enterade®) on chemotherapy related diarrhea and quality of life in solid tumor cancer patients: A non-randomized experimental study. European Journal of Oncology Nursing 2022. [DOI: 10.1016/j.ejon.2022.102186] [Reference Citation Analysis]
197 Tsai WC, Bai LY, Chen YJ, Chu PC, Hsu YW, Sargeant AM, Weng JR. OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling. Oncotarget 2017;8:29233-46. [PMID: 28418923 DOI: 10.18632/oncotarget.16450] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
198 Hann A, Bohle W, Egger J, Zoller W. Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer. Sci Rep 2017;7:41549. [PMID: 28139684 DOI: 10.1038/srep41549] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
199 Chandra V, McAllister F. Therapeutic potential of microbial modulation in pancreatic cancer. Gut 2021:gutjnl-2019-319807. [PMID: 33906958 DOI: 10.1136/gutjnl-2019-319807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
200 Janssen QP, van Dam JL, Kivits IG, Besselink MG, van Eijck CHJ, Homs MYV, Nuyttens JJME, Qi H, van Santvoort HJ, Wei AC, de Wilde RF, Wilmink JW, van Tienhoven G, Groot Koerkamp B. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Ann Surg Oncol 2021. [PMID: 34142290 DOI: 10.1245/s10434-021-10276-8] [Reference Citation Analysis]
201 Zhong S, Qie S, Yang L, Yan Q, Ge L, Wang Z. S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials. Medicine (Baltimore). 2017;96:e7611. [PMID: 28746215 DOI: 10.1097/md.0000000000007611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
202 Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012;17:192-200. [PMID: 22250057 DOI: 10.1634/theoncologist.2011-0268] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
203 Rouanet M, Lebrin M, Gross F, Bournet B, Cordelier P, Buscail L. Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes. Int J Mol Sci 2017;18:E1231. [PMID: 28594388 DOI: 10.3390/ijms18061231] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
204 Le DT, Jaffee EM. Harnessing immune responses in the tumor microenvironment: all signals needed. Clin Cancer Res. 2013;19:6061-6063. [PMID: 24097857 DOI: 10.1158/1078-0432.ccr-13-2424] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
205 Khurana N, Dodhiawala PB, Bulle A, Lim KH. Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer. Cancers (Basel) 2020;12:E2675. [PMID: 32961746 DOI: 10.3390/cancers12092675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
206 Trajkovic-Arsic M, Heid I, Steiger K, Gupta A, Fingerle A, Wörner C, Teichmann N, Sengkwawoh-Lueong S, Wenzel P, Beer AJ, Esposito I, Braren R, Siveke JT. Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma. Sci Rep 2017;7:17038. [PMID: 29213099 DOI: 10.1038/s41598-017-16826-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
207 Kobayashi S, Ueno M, Ishii H, Furuse J. Management of elderly patients with unresectable pancreatic cancer. Jpn J Clin Oncol 2022:hyac101. [PMID: 35789391 DOI: 10.1093/jjco/hyac101] [Reference Citation Analysis]
208 Parkin A, Man J, Timpson P, Pajic M. Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. FEBS J 2019;286:3510-39. [PMID: 31330086 DOI: 10.1111/febs.15011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
209 Deshwar AB, Sugar E, Torto D, De Jesus-Acosta A, Weiss MJ, Wolfgang CL, Le D, He J, Burkhart R, Zheng L, Laheru D, Yarchoan M. Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis. Ann Pancreat Cancer 2018;1:13. [PMID: 29683142 DOI: 10.21037/apc.2018.02.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
210 Liu M, Yang J, Zhang Y, Zhou Z, Cui X, Zhang L, Fung KM, Zheng W, Allard FD, Yee EU, Ding K, Wu H, Liang Z, Zheng L, Fernandez-Zapico ME, Li YP, Bronze MS, Morris KT, Postier RG, Houchen CW, Yang J, Li M. ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism. Clin Cancer Res 2018;24:3186-96. [PMID: 29615456 DOI: 10.1158/1078-0432.CCR-18-0263] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
211 Shirai Y, Saito N, Uwagawa T, Shiba H, Horiuchi T, Iwase R, Haruki K, Ohashi T, Yanaga K. Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB. Oncotarget 2018;9:15292-301. [PMID: 29632644 DOI: 10.18632/oncotarget.24577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
212 Milanović D, Firat E, Grosu AL, Niedermann G. Increased radiosensitivity and radiothermosensitivity of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitor NVP-HSP990. Radiat Oncol 2013;8:42. [PMID: 23448094 DOI: 10.1186/1748-717X-8-42] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
213 Chen PY, Muzumdar MD, Dorans KJ, Robbins R, Bhutkar A, Del Rosario A, Mertins P, Qiao J, Schafer AC, Gertler F, Carr S, Jacks T. Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Res 2018;78:985-1002. [PMID: 29279356 DOI: 10.1158/0008-5472.CAN-17-2129] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
214 Habermehl D, Brecht IC, Bergmann F, Rieken S, Werner J, Büchler MW, Springfeld C, Jäger D, Debus J, Combs SE. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. World J Surg Oncol 2015;13:149. [PMID: 25889749 DOI: 10.1186/s12957-015-0560-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
215 Shimizu K, Chiba S, Hori Y. Identification of a novel subpopulation of tumor-initiating cells from gemcitabine-resistant pancreatic ductal adenocarcinoma patients. PLoS One 2013;8:e81283. [PMID: 24278411 DOI: 10.1371/journal.pone.0081283] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
216 Ladekarl M, Rasmussen LS, Kirkegård J, Chen I, Pfeiffer P, Weber B, Skuladottir H, Østerlind K, Larsen JS, Mortensen FV, Engberg H, Møller H, Fristrup CW. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. Acta Oncol 2022;61:277-85. [PMID: 34879787 DOI: 10.1080/0284186X.2021.2012252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 King DA, Rahalkar S, Bingham DB, Fisher GA. Pancreatic INI1-deficient undifferentiated rhabdoid carcinoma achieves complete clinical response on gemcitabine and nab-paclitaxel following immediate progression on FOLFIRINOX: a case report. J Gastrointest Oncol 2021;12:874-9. [PMID: 34012674 DOI: 10.21037/jgo-20-478] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM, George TJ Jr. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med 2015;4:1224-39. [PMID: 25766842 DOI: 10.1002/cam4.444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
219 Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol 2020;17:487-505. [PMID: 32393771 DOI: 10.1038/s41575-020-0300-1] [Cited by in Crossref: 194] [Cited by in F6Publishing: 162] [Article Influence: 97.0] [Reference Citation Analysis]
220 Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, Lacy C, Maitra A, Hanna N, Alexander HR, Hussain SP. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS One. 2012;7:e31507. [PMID: 22363658 DOI: 10.1371/journal.pone.0031507] [Cited by in Crossref: 111] [Cited by in F6Publishing: 108] [Article Influence: 11.1] [Reference Citation Analysis]
221 van Rijssen LB, Narwade P, van Huijgevoort NC, Tseng DS, van Santvoort HC, Molenaar IQ, van Laarhoven HW, van Eijck CH, Busch OR, Besselink MG; Dutch Pancreatic Cancer Group. Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysis. HPB (Oxford) 2016;18:559-66. [PMID: 27346135 DOI: 10.1016/j.hpb.2016.05.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
222 Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol 2016;13:750-65. [PMID: 27531700 DOI: 10.1038/nrclinonc.2016.119] [Cited by in Crossref: 115] [Cited by in F6Publishing: 113] [Article Influence: 19.2] [Reference Citation Analysis]
223 Cho IK, Kim H, Lee JC, Lee J, Kim J, Ahn S, Park H, Hwang JH. Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. Gut Liver 2020;14:521-8. [PMID: 31615191 DOI: 10.5009/gnl19180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
224 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.3322/caac.21190] [Cited by in Crossref: 479] [Cited by in F6Publishing: 473] [Article Influence: 53.2] [Reference Citation Analysis]
225 Leigh N, Solomon D, Pletcher E, Labow DM, Magge DR, Sarpel U, Golas BJ. Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies? World J Surg Oncol 2020;18:124. [PMID: 32527272 DOI: 10.1186/s12957-020-01898-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
226 Peng JS, Mino J, Monteiro R, Morris-Stiff G, Ali NS, Wey J, El-Hayek KM, Walsh RM, Chalikonda S. Diagnostic Laparoscopy Prior to Neoadjuvant Therapy in Pancreatic Cancer Is High Yield: an Analysis of Outcomes and Costs. J Gastrointest Surg 2017;21:1420-7. [PMID: 28597320 DOI: 10.1007/s11605-017-3470-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
227 Wong SK, Gondara L, Renouf DJ, Lim HJ, Loree JM, Davies JM, Gill S. Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy. J Gastrointest Oncol 2021;12:446-54. [PMID: 34012638 DOI: 10.21037/jgo-20-422] [Reference Citation Analysis]
228 Liu Q, Liao Q, Zhao Y. Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int 2017;17:68. [PMID: 28694739 DOI: 10.1186/s12935-017-0437-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
229 Ansari D, Chen BC, Dong L, Zhou MT, Andersson R. Pancreatic cancer: Translational research aspects and clinical implications. World J Gastroenterol 2012; 18(13): 1417-1424 [PMID: 22509073 DOI: 10.3748/wjg.v18.i13.1417] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
230 Kulemann B, Rösch S, Seifert S, Timme S, Bronsert P, Seifert G, Martini V, Kuvendjiska J, Glatz T, Hussung S, Fritsch R, Becker H, Pitman MB, Hoeppner J. Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Sci Rep 2017;7:4510. [PMID: 28674438 DOI: 10.1038/s41598-017-04601-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
231 Miao L, Li J, Liu Q, Feng R, Das M, Lin CM, Goodwin TJ, Dorosheva O, Liu R, Huang L. Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. ACS Nano 2017;11:8690-706. [PMID: 28809532 DOI: 10.1021/acsnano.7b01786] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 16.6] [Reference Citation Analysis]
232 Farge D, Bournet B, Conroy T, Vicaut E, Rak J, Zogoulous G, Barkun J, Ouaissi M, Buscail L, Frere C. Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. Cancers (Basel). 2020;12. [PMID: 32155940 DOI: 10.3390/cancers12030618] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
233 Okada KI, Kawai M, Hirono S, Miyazawa M, Kitahata Y, Kobayashi R, Ueno M, Hayami S, Shimokawa T, Yamaue H. Impact of Ninjin'Yoeito on Fatigue in Patients Receiving Nab-Paclitaxel Plus Gemcitabine Therapy: A Prospective, Single-Arm, Phase II Open Label, Nonrandomized, Historically-Controlled Study. Curr Ther Res Clin Exp 2020;93:100605. [PMID: 33014206 DOI: 10.1016/j.curtheres.2020.100605] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
234 Dunlop CR, Wallez Y, Johnson TI, Bernaldo de Quirós Fernández S, Durant ST, Cadogan EB, Lau A, Richards FM, Jodrell DI. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models. Br J Cancer 2020;123:1424-36. [PMID: 32741974 DOI: 10.1038/s41416-020-1016-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
235 Heger U, Hackert T. Can local ablative techniques replace surgery for locally advanced pancreatic cancer? J Gastrointest Oncol 2021;12:2536-46. [PMID: 34790414 DOI: 10.21037/jgo-20-379] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
236 Wadd N, Peedell C, Polwart C. Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England. Clin Oncol (R Coll Radiol) 2022:S0936-6555(22)00221-7. [PMID: 35584974 DOI: 10.1016/j.clon.2022.04.012] [Reference Citation Analysis]
237 Er JL, Goh PN, Lee CY, Tan YJ, Hii LW, Mai CW, Chung FF, Leong CO. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC). Apoptosis 2018;23:343-55. [PMID: 29740790 DOI: 10.1007/s10495-018-1459-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
238 Chen K, Qian W, Li J, Jiang Z, Cheng L, Yan B, Cao J, Sun L, Zhou C, Lei M, Duan W, Ma J, Ma Q, Ma Z. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Mol Oncol 2017;11:1475-92. [PMID: 28783244 DOI: 10.1002/1878-0261.12116] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
239 Uwagawa T, Yanaga K. Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. Surg Today 2015;45:1481-8. [PMID: 25673034 DOI: 10.1007/s00595-015-1129-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
240 Kudgus RA, Szabolcs A, Khan JA, Walden CA, Reid JM, Robertson JD, Bhattacharya R, Mukherjee P. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. PLoS One 2013;8:e57522. [PMID: 23483913 DOI: 10.1371/journal.pone.0057522] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
241 Hagiwara Y, Ohashi Y, Okusaka T, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Cheng AL, Kihara K, Sato A, Tanaka M. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open 2017;2:e000151. [PMID: 28761731 DOI: 10.1136/esmoopen-2016-000151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
242 Zhu SK, Xu T, Wang R. Prospects and challenges of immunotherapy for pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2019; 27(1): 6-12 [DOI: 10.11569/wcjd.v27.i1.6] [Reference Citation Analysis]
243 Hama Y, Tate E. High-dose planned adaptive intensity-modulated radiation therapy with simultaneous integrated boost for synchronous oligometastatic pancreatic cancer. Cancer Invest 2022;:1-13. [PMID: 35236196 DOI: 10.1080/07357907.2022.2049287] [Reference Citation Analysis]
244 Lelond S, Ward J, Lambert PJ, Kim CA. Symptom Burden of Patients with Advanced Pancreas Cancer (APC): A Provincial Cancer Institute Observational Study. Curr Oncol 2021;28:2789-800. [PMID: 34436010 DOI: 10.3390/curroncol28040244] [Reference Citation Analysis]
245 Wang Y, Camateros P, Cheung WY. A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers. J Gastrointest Cancer. 2019;50:62-68. [PMID: 29143916 DOI: 10.1007/s12029-017-0028-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
246 Vaziri-Gohar A, Zarei M, Brody JR, Winter JM. Metabolic Dependencies in Pancreatic Cancer. Front Oncol. 2018;8:617. [PMID: 30631752 DOI: 10.3389/fonc.2018.00617] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
247 Kimbara S, Kondo S. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol 2016; 22(33): 7440-7452 [PMID: 27672267 DOI: 10.3748/wjg.v22.i33.7440] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
248 Strippoli A, Rossi S, Martini M, Basso M, D'Argento E, Schinzari G, Barile R, Cassano A, Barone C. ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. Oncotarget 2016;7:35159-68. [PMID: 27147577 DOI: 10.18632/oncotarget.9063] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
249 Jones O, Cheng X, Murthy SRK, Ly L, Zhuang T, Basadonna G, Keidar M, Canady J. The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro. Sci Rep 2021;11:8967. [PMID: 33903679 DOI: 10.1038/s41598-021-88451-w] [Reference Citation Analysis]
250 Muzumdar MD, Chen PY, Dorans KJ, Chung KM, Bhutkar A, Hong E, Noll EM, Sprick MR, Trumpp A, Jacks T. Survival of pancreatic cancer cells lacking KRAS function. Nat Commun 2017;8:1090. [PMID: 29061961 DOI: 10.1038/s41467-017-00942-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 14.0] [Reference Citation Analysis]
251 LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs. 2013;31:943-948. [PMID: 23263993 DOI: 10.1007/s10637-012-9916-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
252 Sugumar K, Hue JJ, Hardacre JM, Ammori JB, Rothermel LD, Dorth J, Saltzman J, Mohamed A, Selfridge JE, Bajor D, Winter JM, Ocuin LM. Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreatic adenocarcinoma. HPB (Oxford) 2021:S1365-182X(21)01582-3. [PMID: 34465529 DOI: 10.1016/j.hpb.2021.08.938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Bailey CH, Jameson G, Sima C, Fleck S, White E, Von Hoff DD, Weiss GJ. Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J Cancer 2012;3:7-13. [PMID: 22211140 DOI: 10.7150/jca.3.7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
254 Gujral TS, Kirschner MW. Hippo pathway mediates resistance to cytotoxic drugs. Proc Natl Acad Sci U S A 2017;114:E3729-38. [PMID: 28416665 DOI: 10.1073/pnas.1703096114] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
255 Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Cancer Lett. 2015;358:59-66. [PMID: 25527450 DOI: 10.1016/j.canlet.2014.12.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
256 Du L, Che Z, Wang-Gillam A. Promising therapeutics of gastrointestinal cancers in clinical trials. J Gastrointest Oncol 2017;8:524-33. [PMID: 28736639 DOI: 10.21037/jgo.2017.01.08] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
257 Miller AL, Garcia PL, Fehling SC, Gamblin TL, Vance RB, Council LN, Chen D, Yang ES, van Waardenburg RCAM, Yoon KJ. The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers (Basel) 2021;13:3470. [PMID: 34298684 DOI: 10.3390/cancers13143470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Zhang QE, Wu Q, Harari PM, Rosenthal DI. Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216. Head Neck 2019;41:37-45. [PMID: 30549358 DOI: 10.1002/hed.25359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
259 Hao S, Mitsakos A, Popowicz P, Irish W, Snyder RA, Parikh AA. Differential effects of the Affordable Care Act on the stage at presentation and receipt of treatment for pancreatic adenocarcinoma. J Surg Oncol 2022. [PMID: 35699593 DOI: 10.1002/jso.26984] [Reference Citation Analysis]
260 Yoshida M, Miyasaka Y, Ohuchida K, Okumura T, Zheng B, Torata N, Fujita H, Nabae T, Manabe T, Shimamoto M, Ohtsuka T, Mizumoto K, Nakamura M. Calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model. Cancer Sci 2016;107:1443-52. [PMID: 27487486 DOI: 10.1111/cas.13024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
261 Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg 2013;257:17-26. [PMID: 22895395 DOI: 10.1097/SLA.0b013e31825ffbfb] [Cited by in Crossref: 120] [Cited by in F6Publishing: 64] [Article Influence: 13.3] [Reference Citation Analysis]
262 El-Behaedi S, Landsman R, Rudloff M, Kolyvas E, Albalawy R, Zhang X, Bera T, Collins K, Kozlov S, Alewine C. Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors. Toxins (Basel) 2018;10:E447. [PMID: 30384408 DOI: 10.3390/toxins10110447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
263 Martinelli P, Carrillo-de Santa Pau E, Cox T, Sainz B Jr, Dusetti N, Greenhalf W, Rinaldi L, Costello E, Ghaneh P, Malats N, Büchler M, Pajic M, Biankin AV, Iovanna J, Neoptolemos J, Real FX. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut 2017;66:1665-76. [PMID: 27325420 DOI: 10.1136/gutjnl-2015-311256] [Cited by in Crossref: 132] [Cited by in F6Publishing: 108] [Article Influence: 26.4] [Reference Citation Analysis]
264 Nasser NJ, Gorenberg M, Agbarya A. First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals (Basel) 2020;13:E373. [PMID: 33171686 DOI: 10.3390/ph13110373] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
265 Langdon CG, Platt JT, Means RE, Iyidogan P, Mamillapalli R, Klein M, Held MA, Lee JW, Koo JS, Hatzis C, Hochster HS, Stern DF. Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor. Mol Cancer Ther 2017;16:1041-53. [PMID: 28292938 DOI: 10.1158/1535-7163.MCT-16-0794] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
266 Mao YH, Yu CZ. Current situation and predicament of multidisciplinary treatment of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2015; 23(36): 5750-5759 [DOI: 10.11569/wcjd.v23.i36.5750] [Reference Citation Analysis]
267 Girelli R, Prejanò S, Cataldo I, Corbo V, Martini L, Scarpa A, Claudio B. Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. Radiol Oncol 2015;49:147-54. [PMID: 26029026 DOI: 10.1515/raon-2015-0013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
268 Desai AM, Lichtman SM. Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biol Med. 2015;12:284-291. [PMID: 26779365 DOI: 10.7497/j.issn.2095-3941.2015.0078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
269 Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 2016;22:278-87. [PMID: 26855150 DOI: 10.1038/nm.4038] [Cited by in Crossref: 127] [Cited by in F6Publishing: 105] [Article Influence: 21.2] [Reference Citation Analysis]
270 Labori KJ, Katz MH, Tzeng CW, Bjørnbeth BA, Cvancarova M, Edwin B, Kure EH, Eide TJ, Dueland S, Buanes T, Gladhaug IP. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. Acta Oncol 2016;55:265-77. [PMID: 26213211 DOI: 10.3109/0284186X.2015.1068445] [Cited by in Crossref: 86] [Cited by in F6Publishing: 49] [Article Influence: 12.3] [Reference Citation Analysis]
271 Ding L, Madamsetty VS, Kiers S, Alekhina O, Ugolkov A, Dube J, Zhang Y, Zhang JS, Wang E, Dutta SK, Schmitt DM, Giles FJ, Kozikowski AP, Mazar AP, Mukhopadhyay D, Billadeau DD. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response. Clin Cancer Res 2019;25:6452-62. [PMID: 31533931 DOI: 10.1158/1078-0432.CCR-19-0799] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
272 Kumar V, Mundra V, Peng Y, Wang Y, Tan C, Mahato RI. Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice. Theranostics 2018;8:4033-49. [PMID: 30128034 DOI: 10.7150/thno.24945] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
273 Martín AJ, Alfonso PG, Rupérez AB, Jiménez MM. Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2. Oncol Lett 2016;12:727-30. [PMID: 27347207 DOI: 10.3892/ol.2016.4667] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
274 van Mackelenbergh MG, Stroes CI, Spijker R, van Eijck CHJ, Wilmink JW, Bijlsma MF, van Laarhoven HWM. Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 31035512 DOI: 10.3390/cancers11050588] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
275 Brar G, Blais EM, Joseph Bender R, Brody JR, Sohal D, Madhavan S, Picozzi VJ, Hendifar AE, Chung VM, Halverson D, Mikhail S, Matrisian LM, Rahib L, Petricoin E, Pishvaian MJ. Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. Br J Cancer 2019;121:264-70. [PMID: 31292535 DOI: 10.1038/s41416-019-0507-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
276 Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, Yang J, Wolpin B. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Invest New Drugs 2016;34:319-28. [PMID: 26994014 DOI: 10.1007/s10637-016-0343-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
277 Han SY, Kim DU, Seol YM, Kim S, Lee NK, Hong SB, Seo HI. First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy. World J Clin Cases 2020; 8(18): 4022-4033 [PMID: 33024759 DOI: 10.12998/wjcc.v8.i18.4022] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
278 Terlizzi M, Buscail E, Boussari O, Adgié S, Leduc N, Terrebonne E, Smith D, Blanc JF, Lapuyade B, Laurent C, Chiche L, Belleannée G, Le Malicot K, Trouette R, Pouypoudat C, Vendrely V. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery. Acta Oncol 2021;60:1114-21. [PMID: 34197269 DOI: 10.1080/0284186X.2021.1944662] [Reference Citation Analysis]
279 Wang W, Zhang T, Zhao W, Xu L, Yang Y, Liao Q, Zhao Y. A Single Talent Immunogenic Membrane Antigen and Novel Prognostic Predictor: voltage-dependent anion channel 1 (VDAC1) in Pancreatic Cancer. Sci Rep 2016;6:33648. [PMID: 27659305 DOI: 10.1038/srep33648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
280 Pompa TA, Morano WF, Jeurkar C, Li H, Soundararajan S, Poli J, Bowne WB, Styler M. Complete Response after Treatment with Neoadjuvant Chemoradiation with Prolonged Chemotherapy for Locally Advanced, Unresectable Adenocarcinoma of the Pancreas. Case Rep Oncol Med 2017;2017:7834702. [PMID: 28373919 DOI: 10.1155/2017/7834702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
281 Costa Neves M, Giakoustidis A, Stamp G, Gaya A, Mudan S. Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101. Cureus 2015;7:e435. [PMID: 26870619 DOI: 10.7759/cureus.435] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
282 Park SJ, Kim JH, Joo I, Han JK. Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT. Abdom Radiol (NY) 2021;46:4765-78. [PMID: 34085090 DOI: 10.1007/s00261-021-03127-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
283 Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. World J Gastrointest Oncol 2018; 10(12): 505-515 [PMID: 30595804 DOI: 10.4251/wjgo.v10.i12.505] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
284 Trebska-McGowan K, Chaib M, Alvarez MA, Kansal R, Pingili AK, Shibata D, Makowski L, Glazer ES. TGF-β Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg 2021. [PMID: 34260016 DOI: 10.1007/s11605-021-05087-x] [Reference Citation Analysis]
285 Suto H, Okano K, Oshima M, Ando Y, Matsukawa H, Takahashi S, Shibata T, Kamada H, Masaki T, Suzuki Y. Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy. J Surg Oncol 2022. [PMID: 35289928 DOI: 10.1002/jso.26854] [Reference Citation Analysis]
286 Kim HW, Lee JC, Paik KH, Lee YS, Hwang JH, Kim J. Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma. Medicine (Baltimore) 2015;94:e1012. [PMID: 26107667 DOI: 10.1097/MD.0000000000001012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
287 Hendricks-Wenger A, Aycock KN, Nagai-Singer MA, Coutermarsh-Ott S, Lorenzo MF, Gannon J, Uh K, Farrell K, Beitel-White N, Brock RM, Simon A, Morrison HA, Tuohy J, Clark-Deener S, Vlaisavljevich E, Davalos RV, Lee K, Allen IC. Establishing an immunocompromised porcine model of human cancer for novel therapy development with pancreatic adenocarcinoma and irreversible electroporation. Sci Rep 2021;11:7584. [PMID: 33828203 DOI: 10.1038/s41598-021-87228-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
288 Tsai CS, Park JW, Chen LT. Nanovector-based therapies in advanced pancreatic cancer. J Gastrointest Oncol 2011;2:185-94. [PMID: 22811849 DOI: 10.3978/j.issn.2078-6891.2011.034] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
289 Harano Y, Babazono A, Fujita T, Jiang P. Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort study. Journal of Geriatric Oncology 2019;10:420-6. [DOI: 10.1016/j.jgo.2018.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
290 Tröger W, Galun D, Reif M, Schumann A, Stanković N, Milićević M. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Dtsch Arztebl Int 2014;111:493-502, 33 p following 502. [PMID: 25142075 DOI: 10.3238/arztebl.2014.0493] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
291 Wishart G, Gupta P, Schettino G, Nisbet A, Velliou E. 3d tissue models as tools for radiotherapy screening for pancreatic cancer. Br J Radiol 2021;94:20201397. [PMID: 33684308 DOI: 10.1259/bjr.20201397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
292 Chan SL, Chan ST, Chan EH, He ZX. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin J Cancer 2014;33:267-76. [PMID: 24472302 DOI: 10.5732/cjc.013.10134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
293 Lekka K, Tzitzi E, Giakoustidis A, Papadopoulos V, Giakoustidis D. Contemporary management of borderline resectable pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg 2019;23:97-108. [PMID: 31225409 DOI: 10.14701/ahbps.2019.23.2.97] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
294 Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. Ann Surg Oncol 2022. [PMID: 35294658 DOI: 10.1245/s10434-022-11503-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 Sun L, Mathews LA, Cabarcas SM, Zhang X, Yang A, Zhang Y, Young MR, Klarmann KD, Keller JR, Farrar WL. Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells. Stem Cells. 2013;31:1454-1466. [PMID: 23592398 DOI: 10.1002/stem.1394] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 9.8] [Reference Citation Analysis]
296 Castino GF, Cortese N, Capretti G, Serio S, Di Caro G, Mineri R, Magrini E, Grizzi F, Cappello P, Novelli F, Spaggiari P, Roncalli M, Ridolfi C, Gavazzi F, Zerbi A, Allavena P, Marchesi F. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Oncoimmunology 2016;5:e1085147. [PMID: 27141376 DOI: 10.1080/2162402X.2015.1085147] [Cited by in Crossref: 75] [Cited by in F6Publishing: 47] [Article Influence: 10.7] [Reference Citation Analysis]
297 Ruskin A, Falker CG, Edens EL, Bauer MR. An Interdisciplinary Approach to Metastatic Pancreatic Cancer and Comorbid Opioid Use Disorder Treatment Within a VA Health Care System. Fed Pract 2021;38:S66-71. [PMID: 34733097 DOI: 10.12788/fp.0160] [Reference Citation Analysis]
298 Sorber R, Teper Y, Abisoye-Ogunniyan A, Waterfall JJ, Davis S, Killian JK, Pineda M, Ray S, McCord MR, Pflicke H, Burkett SS, Meltzer PS, Rudloff U. Whole Genome Sequencing of Newly Established Pancreatic Cancer Lines Identifies Novel Somatic Mutation (c.2587G>A) in Axon Guidance Receptor Plexin A1 as Enhancer of Proliferation and Invasion. PLoS One 2016;11:e0149833. [PMID: 26962861 DOI: 10.1371/journal.pone.0149833] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
299 Kieler M, Unseld M, Bianconi D, Scheithauer W, Prager GW. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid. Ther Adv Med Oncol. 2019;11:1758835919853196. [PMID: 31360237 DOI: 10.1177/1758835919853196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
300 Bansod S, Dodhiawala PB, Lim KH. Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities. Cancers (Basel) 2021;13:5481. [PMID: 34771644 DOI: 10.3390/cancers13215481] [Reference Citation Analysis]
301 Vater LB, Lefebvre B, Turk A, Clasen SC. Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge. Curr Oncol Rep. [DOI: 10.1007/s11912-022-01256-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
302 Pimienta M, Edderkaoui M, Wang R, Pandol S. The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. Front Physiol 2017;8:381. [PMID: 28626429 DOI: 10.3389/fphys.2017.00381] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
303 Chen J, Chen L, Yu J, Xu Y, Wang X, Zeng Z, Liu N, Xu F, Yang S. Meta‑analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment‑associated toxicities. Mol Med Rep 2019;19:477-89. [PMID: 30431091 DOI: 10.3892/mmr.2018.9638] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Temraz S, Shamseddine A, Mukherji D, Charafeddine M, Tfayli A, Assi H, Hammoud MS, Makki I, Nassif S. Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis. Pathol Oncol Res 2019;25:1059-66. [PMID: 30187215 DOI: 10.1007/s12253-018-0464-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
305 Hamad A, Underhill J, Ansari A, Thayaparan V, Cloyd JM, Li Y, Pawlik TM, Tsung A, Abushahin L, Ejaz A. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Surgery 2022:S0039-6060(21)01252-6. [PMID: 35115154 DOI: 10.1016/j.surg.2021.12.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
306 Jafari R, Cramer GM, Celli JP. Modulation of Extracellular Matrix Rigidity Via Riboflavin-mediated Photocrosslinking Regulates Invasive Motility and Treatment Response in a 3D Pancreatic Tumor Model. Photochem Photobiol 2020;96:365-72. [PMID: 31820435 DOI: 10.1111/php.13191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
307 Sato S, Nakamura T, Katagiri T, Tsuchikawa T, Kushibiki T, Hontani K, Takahashi M, Inoko K, Takano H, Abe H, Takeuchi S, Ono M, Kuwabara S, Umemoto K, Suzuki T, Sato O, Nakamura Y, Hirano S. Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. Oncotarget 2017;8:113662-72. [PMID: 29371937 DOI: 10.18632/oncotarget.21939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
308 Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Okubo Y, Nakamura J, Takasumi M, Hashimoto M, Kato T, Kobashi R, Hikichi T, Ohira H. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer 2021;21:1319. [PMID: 34886831 DOI: 10.1186/s12885-021-09069-9] [Reference Citation Analysis]
309 Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis 2018;7:87. [PMID: 30442938 DOI: 10.1038/s41389-018-0096-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
310 Fan YF, Qin Y, Li DG, Kerr D. Retrospective Clinical Study of Advanced Pancreatic Cancer Treated With Chemotherapy and Abdominal Hyperthermia.J Glob Oncol. 2018;4:1-4. [PMID: 30241198 DOI: 10.1200/JGO.2017.009985] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
311 Liu S, Qin Z, Xu J, Zeng J, Chen J, Niu L, Xu M. Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study. Onco Targets Ther. 2019;12:1341-1350. [PMID: 30863100 DOI: 10.2147/ott.s186721] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
312 Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology 2015;4:e1008866. [PMID: 26137404 DOI: 10.1080/2162402X.2015.1008866] [Cited by in Crossref: 144] [Cited by in F6Publishing: 108] [Article Influence: 20.6] [Reference Citation Analysis]
313 Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang DZ, Kim G, Stella P, Richel D, Szcylik C, Cascinu S, Frassineti GL, Ciuleanu T, Hurt K, Hynes S, Lin J, Lin AB, Von Hoff D, Calvo E. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer 2017;17:137. [PMID: 28202004 DOI: 10.1186/s12885-017-3131-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
314 Kumar K, DeCant BT, Grippo PJ, Hwang RF, Bentrem DJ, Ebine K, Munshi HG. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo. JCI Insight 2017;2:e88032. [PMID: 28194432 DOI: 10.1172/jci.insight.88032] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
315 Froeling FEM, Casolino R, Pea A, Biankin AV, Chang DK. Molecular Subtyping and Precision Medicine for Pancreatic Cancer. J Clin Med 2021;10:E149. [PMID: 33406790 DOI: 10.3390/jcm10010149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
316 Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol 2013; 19(28): 4511-4519 [PMID: 23901226 DOI: 10.3748/wjg.v19.i28.4511] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
317 Buanes T, Edwin B. Long term oncological outcome of laparoscopic techniques in pancreatic cancer. World J Gastrointest Endosc 2018; 10(12): 383-391 [PMID: 30631402 DOI: 10.4253/wjge.v10.i12.383] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
318 Akce M, Zaidi MY, Waller EK, El-Rayes BF, Lesinski GB. The Potential of CAR T Cell Therapy in Pancreatic Cancer. Front Immunol. 2018;9:2166. [PMID: 30319627 DOI: 10.3389/fimmu.2018.02166] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
319 Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019;68:742-58. [PMID: 30396902 DOI: 10.1136/gutjnl-2018-316822] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 11.3] [Reference Citation Analysis]
320 Lloyd S, Chang BW. New possibilities and potential benefits for local control in locally recurrent pancreatic cancer. J Gastrointest Oncol 2013;4:340-2. [PMID: 24294504 DOI: 10.3978/j.issn.2078-6891.2013.049] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
321 Duval L, Lam YH, Pons-Tostivint E, Bennouna J, Matysiak-Budnik T, Lepeintre A, Girot P, Touchefeu Y. [Re-visiting the Pronopall score ten years later: A multicenter retrospective study]. Bull Cancer 2022:S0007-4551(22)00016-9. [PMID: 35094840 DOI: 10.1016/j.bulcan.2021.12.016] [Reference Citation Analysis]
322 Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol. 2014;Epub ahead of print. [PMID: 25068471 DOI: 10.1097/coc.0000000000000108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
323 Cappello P, Novelli F. A self antigen reopens the games in pancreatic cancer. Oncoimmunology. 2013;2:e24384. [PMID: 23894698 DOI: 10.4161/onci.24384] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
324 Di Franco G, Usai A, Funel N, Palmeri M, Montesanti IER, Bianchini M, Gianardi D, Furbetta N, Guadagni S, Vasile E, Falcone A, Pollina LE, Raffa V, Morelli L. Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. World J Gastroenterol 2020;26:2792-809. [PMID: 32550755 DOI: 10.3748/wjg.v26.i21.2792] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
325 Simon M, Bioulac-Sage P, Trillaud H, Blanc JF. FOLFOX regimen in pancreatic acinar cell carcinoma: case report and review of the literature. Acta Oncol 2012;51:403-5. [PMID: 21961498 DOI: 10.3109/0284186X.2011.617388] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
326 Kamposioras K, Geraghty J, Appleyard J, Dawod M, Papadimitriou K, Lamarca A, Anthoney A. Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies. J Gastrointest Cancer 2021. [PMID: 34648136 DOI: 10.1007/s12029-021-00718-7] [Reference Citation Analysis]
327 Pandé R, Roberts KJ. Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer-Where Is the Least Harm and Most Benefit? Front Oncol 2019;9:1060. [PMID: 31681596 DOI: 10.3389/fonc.2019.01060] [Reference Citation Analysis]
328 Bittoni A, Santoni M, Lanese A, Pellei C, Andrikou K, Stefano C. Neoadjuvant therapy in pancreatic cancer: an emerging strategy. Gastroenterol Res Pract 2014;2014:183852. [PMID: 25101123 DOI: 10.1155/2014/183852] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
329 Poon D, Tan MH, Khor D. Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor. BMJ Case Rep 2021;14:e244271. [PMID: 34511423 DOI: 10.1136/bcr-2021-244271] [Reference Citation Analysis]
330 Di Valentin T, Alam Y, Ali Alsharm A, Arif S, Aubin F, Biagi J, Booth CM, Bourque S, Burkes R, Champion P, Colwell B, Cripps C, Dallaire M, Dorreen M, Finn N, Frechette D, Gallinger S, Gapski J, Giacomantonio C, Gill S, Goel R, Goodwin R, Grimard L, Grothey A, Hammad N, Hedley D, Jhaveri K, Jonker D, Ko Y, L'espérance M, Maroun J, Ostic H, Perrin N, Rother M, St-Hilaire E, Tehfe M, Thirlwell M, Welch S, Yarom N, Asmis T. Eastern Canadian colorectal cancer consensus conference: application of new modalities of staging and treatment of gastrointestinal cancers. Curr Oncol 2012;19:169-74. [PMID: 22670096 DOI: 10.3747/co.19.931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
331 Nabavizadeh A, Payen T, Iuga AC, Sagalovskiy IR, Desrouilleres D, Saharkhiz N, Palermo CF, Sastra SA, Oberstein PE, Rosario V, Kluger MD, Schrope BA, Chabot JA, Olive KP, Konofagou EE. Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME) in vivo. Theranostics 2020;10:4614-26. [PMID: 32292518 DOI: 10.7150/thno.37965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
332 Muthu P, Lutz S. Quantitative Detection of Nucleoside Analogues by Multi-enzyme Biosensors using Time-Resolved Kinetic Measurements. ChemMedChem 2016;11:660-6. [PMID: 26934468 DOI: 10.1002/cmdc.201600096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
333 Kim HS, Jang JY, Han Y, Lee KB, Joo I, Lee DH, Kim JR, Kim H, Kwon W, Kim SW. Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer. Ann Surg Treat Res 2017;93:186-94. [PMID: 29094028 DOI: 10.4174/astr.2017.93.4.186] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
334 Pencovich N, Orbach L, Lessing Y, Elazar A, Barnes S, Berman P, Blachar A, Nachmany I, Sagie B. Palliative bypass surgery for patients with advanced pancreatic adenocarcinoma: experience from a tertiary center. World J Surg Oncol 2020;18:63. [PMID: 32238149 DOI: 10.1186/s12957-020-01828-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
335 Pishvaian MJ, Joseph Bender R, Matrisian LM, Rahib L, Hendifar A, Hoos WA, Mikhail S, Chung V, Picozzi V, Heartwell C. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget. 2016;8:83446-83456. [PMID: 29137355 DOI: 10.18632/oncotarget.13225] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
336 Hornick JR, Spitzer D, Goedegebuure P, Mach RH, Hawkins WG. Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. Surgery 2012;152:S152-6. [PMID: 22763259 DOI: 10.1016/j.surg.2012.05.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
337 Chiramel J, Backen AC, Pihlak R, Lamarca A, Frizziero M, Tariq NU, Hubner RA, Valle JW, Amir E, McNamara MG. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci 2017;18:E909. [PMID: 28445400 DOI: 10.3390/ijms18050909] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
338 Wang L, Liu Z, Zhou Q, Gu S, Liu X, Huang J, Jiang H, Wang H, Cao L, Sun J, Shen Y, Meng H, Liu X. Prodrug nanoparticles rationally integrating stroma modification and chemotherapy to treat metastatic pancreatic cancer. Biomaterials 2021;278:121176. [PMID: 34656882 DOI: 10.1016/j.biomaterials.2021.121176] [Reference Citation Analysis]
339 Gillson J, Ramaswamy Y, Singh G, Gorfe AA, Pavlakis N, Samra J, Mittal A, Sahni S. Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy? Cancers (Basel). 2020;12. [PMID: 32456277 DOI: 10.3390/cancers12051341] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
340 Knoop RF, Sparn M, Waldmann J, Plassmeier L, Bartsch DK, Lauth M, Hudemann C, Fendrich V. Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer. Neoplasia 2014;16:463-70. [PMID: 24953430 DOI: 10.1016/j.neo.2014.05.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
341 Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, Shin DB. Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy. Cancer Res Treat 2016;48:1264-73. [PMID: 27034148 DOI: 10.4143/crt.2015.250] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
342 Han C, Bellone S, Schwartz PE, Govindan SV, Sharkey RM, Goldenberg DM, Santin AD. Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report. Gynecol Oncol Rep 2018;25:37-40. [PMID: 29977989 DOI: 10.1016/j.gore.2018.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
343 Chen K, Qian W, Jiang Z, Cheng L, Li J, Sun L, Zhou C, Gao L, Lei M, Yan B, Cao J, Duan W, Ma Q. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol Cancer 2017;16:131. [PMID: 28738823 DOI: 10.1186/s12943-017-0701-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]
344 Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA, Erickson BA, Evans DB, Tsai S. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Ann Surg Oncol 2021;28:2246-56. [PMID: 33000372 DOI: 10.1245/s10434-020-09149-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
345 Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
346 Chauhan N, Kruse A, Newby H, Jaggi M, Yallapu MM, Chauhan SC. Pluronic Polymer-Based Ormeloxifene Nanoformulations Induce Superior Anticancer Effects in Pancreatic Cancer Cells. ACS Omega 2020;5:1147-56. [PMID: 31984272 DOI: 10.1021/acsomega.9b03382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
347 Ueno M, Nagashima F, Ueno H, Ikeda M, Ohkawa S, Mizuno N, Ioka T, Omuro Y, Nakajima TE, Furuse J. Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer. Intern Med 2019;58:2957-62. [PMID: 31243233 DOI: 10.2169/internalmedicine.2362-18] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
348 Mei L, Du W, Ma WW. Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. J Gastrointest Oncol. 2016;7:487-494. [PMID: 27284483 DOI: 10.21037/jgo.2016.03.03] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
349 de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet. 2018;. [PMID: 29520731 DOI: 10.1007/s40262-018-0644-7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 30.0] [Reference Citation Analysis]
350 Pan T, Zhang Y, Zhou N, He X, Chen C, Liang L, Duan X, Lin Y, Wu K, Zhang H. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth. Oncotarget 2016;7:44299-309. [PMID: 27322423 DOI: 10.18632/oncotarget.9996] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
351 Spring BQ, Rizvi I, Xu N, Hasan T. The role of photodynamic therapy in overcoming cancer drug resistance. Photochem Photobiol Sci. 2015;14:1476-1491. [PMID: 25856800 DOI: 10.1039/c4pp00495g] [Cited by in Crossref: 142] [Cited by in F6Publishing: 61] [Article Influence: 20.3] [Reference Citation Analysis]
352 Kim TH, Lee WJ, Woo SM, Oh ES, Youn SH, Jang HY, Han SS, Park SJ, Suh YG, Moon SH, Kim SS, Kim DY. Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer. Sci Rep 2020;10:21712. [PMID: 33303947 DOI: 10.1038/s41598-020-78875-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
353 Thibodeau S, Voutsadakis IA. FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II Studies. J Clin Med 2018;7:E7. [PMID: 29300345 DOI: 10.3390/jcm7010007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
354 Filippini DM, Grassi E, Palloni A, Carloni R, Casadei R, Ricci C, Serra C, Ercolani G, Brandi G, Di Marco M. Searching for novel multimodal treatments in oligometastatic pancreatic cancer. BMC Cancer 2020;20:271. [PMID: 32228504 DOI: 10.1186/s12885-020-06718-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
355 Moslim MA, Hall MJ, Meyer JE, Reddy SS. Pancreatic cancer in the era of COVID-19 pandemic: Which one is the lesser of two evils? World J Clin Oncol 2021; 12(2): 54-60 [PMID: 33680873 DOI: 10.5306/wjco.v12.i2.54] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
356 Cabral JGG, Taglieri E, Pelosof A, Rosendo D, Ardengh JC. Comparative Study between Plastic and Metallic Stents for Biliary Decompression in Patients with Distal Biliary Obstruction. Gastroenterol Res Pract 2017;2017:7621821. [PMID: 29018481 DOI: 10.1155/2017/7621821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
357 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
358 Satake T, Morizane C, Maruki Y, Ohba A, Nagashio Y, Kondo S, Hijioka S, Ueno H, Okusaka T. The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. Int J Clin Oncol 2022. [PMID: 35637361 DOI: 10.1007/s10147-022-02186-w] [Reference Citation Analysis]
359 Lonardo E, Cioffi M, Sancho P, Crusz S, Heeschen C. Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies. J Vis Exp 2015;:e52801. [PMID: 26132091 DOI: 10.3791/52801] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
360 Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019;12:130. [PMID: 31801585 DOI: 10.1186/s13045-019-0824-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
361 Oneda E, Zaniboni A. Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature. J Clin Med 2019;8:E1922. [PMID: 31717439 DOI: 10.3390/jcm8111922] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
362 Wang L, Scott FI, Boursi B, Reiss KA, Williams S, Glick H, Yang YX. Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01150-2. [PMID: 34737092 DOI: 10.1016/j.cgh.2021.10.037] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
363 Barrett MT, Deiotte R, Lenkiewicz E, Malasi S, Holley T, Evers L, Posner RG, Jones T, Han H, Sausen M, Velculescu VE, Drebin J, O'Dwyer P, Jameson G, Ramanathan RK, Von Hoff DD. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Br J Cancer 2017;117:572-82. [PMID: 28720843 DOI: 10.1038/bjc.2017.209] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
364 Huang PW, Chang CF, Hung CY, Hsueh SW, Chang PH, Yeh KY, Chen JS, Chen YY, Lu CH, Hung YS, Chou WC. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. Cancer Med 2019;8:5554-63. [PMID: 31385456 DOI: 10.1002/cam4.2483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
365 Byrne JD, Jajja MRN, O'Neill AT, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, DeSimone JM, Yeh JJ. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. Cancer Chemother Pharmacol 2018;81:991-8. [PMID: 29603014 DOI: 10.1007/s00280-018-3570-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
366 Tuli R, Lo S, Koo J, Pishvaian M, Bender RJ, Petricoin E, Brody J, Nissen N. Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma. JCO Precision Oncology 2017. [DOI: 10.1200/po.17.00016] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
367 Mirlekar B, Michaud D, Searcy R, Greene K, Pylayeva-Gupta Y. IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 2018;6:1014-24. [PMID: 29980536 DOI: 10.1158/2326-6066.CIR-17-0710] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
368 Agostini A, Orlacchio A, Carbone C, Guerriero I. Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought. Front Immunol 2022;13:876291. [DOI: 10.3389/fimmu.2022.876291] [Reference Citation Analysis]
369 Emelyanova M, Pokataev I, Shashkov I, Kopantseva E, Lyadov V, Heydarov R, Mikhailovich V. TYMS 3'-UTR Polymorphism: A Novel Association with FOLFIRINOX-Induced Neurotoxicity in Pancreatic Cancer Patients. Pharmaceutics 2021;14:77. [PMID: 35056973 DOI: 10.3390/pharmaceutics14010077] [Reference Citation Analysis]
370 Su K, Peng Y, Yu H, Bukhari I. Development of a Prognostic Model Based on Pyroptosis-Related Genes in Pancreatic Adenocarcinoma. Disease Markers 2022;2022:1-28. [DOI: 10.1155/2022/9141117] [Reference Citation Analysis]
371 Innominato PF, Karaboué A, Focan C, Chollet P, Giacchetti S, Bouchahda M, Ulusakarya A, Torsello A, Adam R, Lévi FA, Garufi C. Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial. Int J Cancer 2020. [PMID: 33270911 DOI: 10.1002/ijc.33422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
372 Luu AM, Herzog T, Hoehn P, Reinacher-Schick A, Munding J, Uhl W, Braumann C. FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. J Gastrointest Oncol 2018;9:E9-E12. [PMID: 29755782 DOI: 10.21037/jgo.2018.01.07] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
373 Hayasaki A, Isaji S, Kishiwada M, Fujii T, Iizawa Y, Kato H, Tanemura A, Murata Y, Azumi Y, Kuriyama N, Mizuno S, Usui M, Sakurai H. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer. Cancers (Basel) 2018;10:E65. [PMID: 29510561 DOI: 10.3390/cancers10030065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
374 Yamamoto KN, Nakamura A, Liu LL, Stein S, Tramontano AC, Kartoun U, Shimizu T, Inoue Y, Asakuma M, Haeno H, Kong CY, Uchiyama K, Gonen M, Hur C, Michor F. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS One 2019;14:e0215409. [PMID: 31026288 DOI: 10.1371/journal.pone.0215409] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
375 Mortoglou M, Wallace D, Buha Djordjevic A, Djordjevic V, Arisan ED, Uysal-onganer P. MicroRNA-Regulated Signaling Pathways: Potential Biomarkers for Pancreatic Ductal Adenocarcinoma. Stresses 2021;1:30-47. [DOI: 10.3390/stresses1010004] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
376 Geboers B, Timmer FEF, Ruarus AH, Pouw JEE, Schouten EAC, Bakker J, Puijk RS, Nieuwenhuizen S, Dijkstra M, van den Tol MP, de Vries JJJ, Oprea-Lager DE, Menke-van der Houven van Oordt CW, van der Vliet HJ, Wilmink JW, Scheffer HJ, de Gruijl TD, Meijerink MR, On Behalf Of The Dutch Pancreatic Cancer Group. Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol. Cancers (Basel) 2021;13:3902. [PMID: 34359801 DOI: 10.3390/cancers13153902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Keum J, Lee HS, Jo JH, Chung MJ, Park JY, Park SW, Song SY, Bang S. Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. Cancers (Basel) 2022;14:1244. [PMID: 35267552 DOI: 10.3390/cancers14051244] [Reference Citation Analysis]
378 Ostapoff KT, Gabriel E, Attwood K, Kuvshinoff BW, Nurkin SJ, Hochwald SN. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma? HPB (Oxford) 2017;19:587-94. [PMID: 28433254 DOI: 10.1016/j.hpb.2017.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
379 Ormanns S, Siveke JT, Heinemann V, Haas M, Sipos B, Schlitter AM, Esposito I, Jung A, Laubender RP, Kruger S, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Geissler M, Greten TF, Kirchner T, Boeck S. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer 2014;14:624. [PMID: 25164437 DOI: 10.1186/1471-2407-14-624] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
380 Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol. 2017;8:566-571. [PMID: 28736643 DOI: 10.21037/jgo.2017.02.02] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
381 Epelbaum R, Shacham-Shmueli E, Klein B, Agbarya A, Brenner B, Brenner R, Gez E, Golan T, Hubert A, Purim O, Temper M, Tepper E, Voss A, Russell K, Dvir A, Soussan-Gutman L, Stemmer SM, Geva R. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. Biomed Res Int 2015;2015:681653. [PMID: 26161408 DOI: 10.1155/2015/681653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
382 De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, Dasari A, Blatchford PJ, Quackenbush K, Messersmith W. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest New Drugs. 2014;32:739-745. [PMID: 24668033 DOI: 10.1007/s10637-014-0083-8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 8.8] [Reference Citation Analysis]
383 Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefèvre L, Bonnetain F, Lévy P, Raymond E, Ruszniewski P, Louvet C, Hammel P. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol 2012; 18(33): 4533-4541 [PMID: 22969226 DOI: 10.3748/wjg.v18.i33.4533] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
384 Jain R, Vijayvergia N, Devarajan K, Lewis B, Denlinger CS, Cohen SJ, Dotan E. Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era. J Geriatr Oncol 2020;11:640-6. [PMID: 31917116 DOI: 10.1016/j.jgo.2019.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
385 Yalcin S, Dane F, Oksuzoglu B, Ozdemir NY, Isikdogan A, Ozkan M, Demirag GG, Coskun HS, Karabulut B, Evrensel T, Ustaoglu MA, Ozdemir F, Turna H, Yavuzsen T, Aykan F, Sevinc A, Akbulut H, Yuce D, Hayran M, Kilickap S. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study. BMC Cancer 2020;20:259. [PMID: 32228512 DOI: 10.1186/s12885-020-06758-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
386 Luo D, Digiovanni MG, Wei R, Lacomb JF, Williams JL, Rigas B, Mackenzie GG. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine. Carcinogenesis 2020;41:927-39. [PMID: 31584613 DOI: 10.1093/carcin/bgz170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
387 Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol 2016;39:340-5. [PMID: 24685886 DOI: 10.1097/COC.0000000000000068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
388 Hank T, Strobel O. Conversion Surgery for Advanced Pancreatic Cancer. J Clin Med 2019;8:E1945. [PMID: 31718103 DOI: 10.3390/jcm8111945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
389 Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, von Weikersthal LF, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, Höhler T, Ko YD, Jung A, Neugebauer S, Boeck S. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013;62:751-9. [PMID: 22773551 DOI: 10.1136/gutjnl-2012-302759] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 8.6] [Reference Citation Analysis]
390 Kleeff J, Stöß C, Yip V, Knoefel WT. [Resection for advanced pancreatic cancer following multimodal therapy]. Chirurg 2016;87:406-12. [PMID: 27138271 DOI: 10.1007/s00104-016-0184-3] [Reference Citation Analysis]
391 Poruk KE, Valero V 3rd, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Ann Surg 2016;264:1073-81. [PMID: 26756760 DOI: 10.1097/SLA.0000000000001600] [Cited by in Crossref: 73] [Cited by in F6Publishing: 50] [Article Influence: 14.6] [Reference Citation Analysis]
392 Golan T, Atias D, Stossel C, Raitses-Gurevich M. Patient-derived xenograft models of BRCA-associated pancreatic cancers. Adv Drug Deliv Rev 2021;171:257-65. [PMID: 33617901 DOI: 10.1016/j.addr.2021.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
393 Boulay BR, Parepally M. Managing malignant biliary obstruction in pancreas cancer: Choosing the appropriate strategy. World J Gastroenterol 2014; 20(28): 9345-9353 [PMID: 25071329 DOI: 10.3748/wjg.v20.i28.9345] [Cited by in F6Publishing: 26] [Reference Citation Analysis]
394 Geismann C, Grohmann F, Sebens S, Wirths G, Dreher A, Häsler R, Rosenstiel P, Hauser C, Egberts JH, Trauzold A, Schneider G, Sipos B, Zeissig S, Schreiber S, Schäfer H, Arlt A. c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells. Cell Death Dis 2014;5:e1455. [PMID: 25299780 DOI: 10.1038/cddis.2014.417] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
395 Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Adjuvant and neoadjuvant treatment in pancreatic cancer. World J Gastroenterol 2012; 18(14): 1565-1572 [PMID: 22529684 DOI: 10.3748/wjg.v18.i14.1565] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
396 Scheithauer W, Kornek G, Prager G, Stranzl N, Laengle F, Schindl M, Friedl J, Klech J, Roethlin S, Zielinski C. Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. J Gastrointest Oncol. 2016;7:234-238. [PMID: 27034791 DOI: 10.3978/j.issn.2078-6891.2015.107] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
397 Zhang H. Onivyde for the therapy of multiple solid tumors. Onco Targets Ther 2016;9:3001-7. [PMID: 27284250 DOI: 10.2147/OTT.S105587] [Cited by in Crossref: 64] [Cited by in F6Publishing: 24] [Article Influence: 10.7] [Reference Citation Analysis]
398 Bateni SB, Gingrich AA, Kirane AR, Sauder CAM, Gholami S, Bold RJ, Meyers FJ, Canter RJ. Chemotherapy After Diagnosis of Malignant Bowel Obstruction is Associated with Superior Survival for Medicare Patients with Advanced Malignancy. Ann Surg Oncol 2021. [PMID: 33829359 DOI: 10.1245/s10434-021-09831-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
399 Qin C, Yang G, Yang J, Ren B, Wang H, Chen G, Zhao F, You L, Wang W, Zhao Y. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer 2020;19:50. [PMID: 32122374 DOI: 10.1186/s12943-020-01169-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
400 Babiker HM, Karass M, Recio-Boiles A, Chandana SR, McBride A, Mahadevan D. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Expert Opin Investig Drugs 2019;28:583-92. [PMID: 31215251 DOI: 10.1080/13543784.2019.1632289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
401 Gong J, Muñoz AR, Pingali S, Payton-Stewart F, Chan DE, Freeman JW, Ghosh R, Kumar AP. Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells. Mol Carcinog 2017;56:402-11. [PMID: 27208550 DOI: 10.1002/mc.22503] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
402 Delitto D, Black BS, Sorenson HL, Knowlton AE, Thomas RM, Sarosi GA, Moldawer LL, Behrns KE, Liu C, George TJ. The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. BMC Cancer. 2015;15:783. [PMID: 26498838 DOI: 10.1186/s12885-015-1820-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
403 Kang S, Yoo C, Lee SH, Oh D, Song TJ, Lee SS, Jeong JH, Park DH, Seo DW, Park J, Hwang DW, Song KB, Lee JH, Lee W, Kwak BJ, Hong S, Chang H, Ryoo B, Kim K, Kim SC. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Ther Adv Med Oncol 2022;14:175883592210971. [DOI: 10.1177/17588359221097190] [Reference Citation Analysis]
404 Polireddy K, Chen Q. Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. J Cancer 2016;7:1497-514. [PMID: 27471566 DOI: 10.7150/jca.14922] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
405 Nakai Y, Chang KJ. EUS-guided fine-needle injection for pancreatic cancer: back to the future. Gastrointest Endosc 2020;92:1053-4. [PMID: 33160487 DOI: 10.1016/j.gie.2020.06.025] [Reference Citation Analysis]
406 Wu W, Wu Q, Hong X, Zhou L, Zhang J, You L, Wang W, Wu H, Dai H, Zhao Y. Catechol-O-methyltransferase, a new target for pancreatic cancer therapy. Cancer Sci 2015;106:576-83. [PMID: 25711924 DOI: 10.1111/cas.12648] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
407 Poh AR, Ernst M. Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges. Cancers (Basel) 2021;13:2860. [PMID: 34201127 DOI: 10.3390/cancers13122860] [Reference Citation Analysis]
408 Park R, Coveler AL, Cavalcante L, Saeed A. GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties. Biology (Basel) 2021;10:610. [PMID: 34356465 DOI: 10.3390/biology10070610] [Reference Citation Analysis]
409 Kobayashi S, Ueno M, Omae K, Kuramochi H, Terao M, Mizuno N, Ozaka M, Ueno H, Uesugi K, Kobayashi N, Kobayashi M, Todaka A, Fukutomi A. Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. Oncotarget 2019;10:1775-84. [PMID: 30956757 DOI: 10.18632/oncotarget.26633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
410 Martinez JO, Evangelopoulos M, Bhavane R, Acciardo S, Salvatore F, Liu X, Ferrari M, Tasciotti E. Multistage Nanovectors Enhance the Delivery of Free and Encapsulated Drugs. Curr Drug Targets 2015;16:1582-90. [PMID: 25316273 DOI: 10.2174/1389450115666141015113914] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
411 Kirkegård J, Bojesen AB, Nielsen MF, Mortensen FV. Trends in pancreatic cancer incidence, characteristics, and outcomes in Denmark 1980-2019: A nationwide cohort study. Cancer Epidemiol 2022;80:102230. [PMID: 35901622 DOI: 10.1016/j.canep.2022.102230] [Reference Citation Analysis]
412 Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol 2015;54:979-85. [PMID: 25734581 DOI: 10.3109/0284186X.2015.1004367] [Cited by in Crossref: 134] [Cited by in F6Publishing: 86] [Article Influence: 19.1] [Reference Citation Analysis]
413 Muramatsu M, Tsuchiya A, Ohta S, Iijima Y, Maruyama M, Onodera Y, Hagihara M, Nakaya N, Sato I, Omura K, Ueno S, Nakajima H. Measuring body composition using the bioelectrical impedance method can predict the outcomes of gemcitabine-based chemotherapy in patients with pancreatobiliary tract cancer. Oncol Lett 2015;10:3535-41. [PMID: 26788165 DOI: 10.3892/ol.2015.3811] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
414 Tiriac H, Plenker D, Baker LA, Tuveson DA. Organoid models for translational pancreatic cancer research. Curr Opin Genet Dev 2019;54:7-11. [PMID: 30844513 DOI: 10.1016/j.gde.2019.02.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
415 Loft M, Lee B, Tie J, Gibbs P. Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. J Pers Med 2019;9:E37. [PMID: 31323810 DOI: 10.3390/jpm9030037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
416 Padhi P, Narula A, Balog A, Christou A. Use of molecular studies for treatment of metastatic pleomorphic large cell pancreatic cancers-a novel strategy. J Gastrointest Oncol 2016;7:E17-21. [PMID: 27034802 DOI: 10.3978/j.issn.2078-6891.2015.118] [Reference Citation Analysis]
417 Lan B, Zeng S, Grützmann R, Pilarsky C. The Role of Exosomes in Pancreatic Cancer. Int J Mol Sci 2019;20:E4332. [PMID: 31487880 DOI: 10.3390/ijms20184332] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
418 Zhou X, Liao X, Wang X, Huang K, Yang C, Yu T, Liu J, Han C, Zhu G, Su H, Qin W, Han Q, Liu Z, Huang J, Gong Y, Ye X, Peng T. Clinical significance and prospective molecular mechanism of C‑C motif chemokine receptors in patients with early‑stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Oncol Rep 2019;42:1856-68. [PMID: 31432181 DOI: 10.3892/or.2019.7277] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
419 Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases 2018;6:E103. [PMID: 30428574 DOI: 10.3390/diseases6040103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
420 Liu X, Tang I, Wainberg ZA, Meng H. Safety Considerations of Cancer Nanomedicine-A Key Step toward Translation. Small 2020;16:e2000673. [PMID: 32406992 DOI: 10.1002/smll.202000673] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
421 Cartwright TH, Parisi M, Espirito JL, Wilson TW, Pelletier C, Patel M, Babiker HM. Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting. Drugs Real World Outcomes 2018;5:149-59. [PMID: 29946913 DOI: 10.1007/s40801-018-0137-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
422 Perri G, Prakash LR, Katz MHG. Response to Preoperative Therapy in Localized Pancreatic Cancer. Front Oncol 2020;10:516. [PMID: 32351893 DOI: 10.3389/fonc.2020.00516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
423 Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol 2019;5:1020-7. [PMID: 31145418 DOI: 10.1001/jamaoncol.2019.0892] [Cited by in Crossref: 141] [Cited by in F6Publishing: 133] [Article Influence: 70.5] [Reference Citation Analysis]
424 Zijlstra M, Bernards N, de Hingh IH, van de Wouw AJ, Goey SH, Jacobs EM, Lemmens VE, Creemers GJ. Does long-term survival exist in pancreatic adenocarcinoma? Acta Oncol 2016;55:259-64. [PMID: 26559995 DOI: 10.3109/0284186X.2015.1096020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
425 Chiorean EG, Cheung WY, Giordano G, Kim G, Al-Batran SE. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Ther Adv Med Oncol. 2019;11:1758835919850367. [PMID: 31205510 DOI: 10.1177/1758835919850367] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
426 Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). J Transl Med 2018;16:207. [PMID: 30031393 DOI: 10.1186/s12967-018-1568-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
427 Collienne M, Loghmani H, Heineman TC, Arnold D. GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers. Future Oncol 2022;:0. [PMID: 35796248 DOI: 10.2217/fon-2022-0453] [Reference Citation Analysis]
428 Zhong J, Patel K, Switchenko J, Cassidy RJ, Hall WA, Gillespie T, Patel PR, Kooby D, Landry J. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 2017;123:3486-3493. [PMID: 28493288 DOI: 10.1002/cncr.30706] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
429 Furniss CS, Yurgelun MB, Ukaegbu C, Constantinou PE, Lafferty CC, Talcove-Berko ER, Schwartz AN, Stopfer JE, Underhill-Blazey M, Kenner B, Nelson SH, Okumura S, Law S, Zhou AY, Coffin TB, Rodriguez NJ, Uno H, Ocean AJ, McAllister F, Lowy AM, Lippman SM, Klein AP, Madlensky L, Petersen GM, Garber JE, Goggins MG, Maitra A, Syngal S. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer Prev Res (Phila) 2021;14:1021-32. [PMID: 34625409 DOI: 10.1158/1940-6207.CAPR-20-0642] [Reference Citation Analysis]
430 Yu KH, Ozer M, Cockrum P, Surinach A, Wang S, Chu BC. Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma. Cancer Med 2021;10:8934-43. [PMID: 34811961 DOI: 10.1002/cam4.4415] [Reference Citation Analysis]
431 Woods N, Trevino J, Coppola D, Chellappan S, Yang S, Padmanabhan J. Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling. Oncotarget 2015;6:35931-48. [PMID: 26440150 DOI: 10.18632/oncotarget.5933] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
432 van der Geest LGM, van Eijck CHJ, Groot Koerkamp B, Lemmens VEPP, Busch OR, Vissers PAJ, Wilmink JW, Besselink MG; Dutch Pancreatic Cancer Group. Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. Cancer Med 2018;7:4943-51. [PMID: 30188015 DOI: 10.1002/cam4.1750] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
433 Liu L, Salnikov AV, Bauer N, Aleksandrowicz E, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Schemmer P, Werner J. Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation. Int J Cancer. 2014;134:2489-2503. [PMID: 24615157 DOI: 10.1002/ijc.28583] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 10.3] [Reference Citation Analysis]
434 Maraveyas A, Haque F, Muazzam IA, Ilyas W, Bozas G. Increased dose primary thromboprophylaxis in ambulatory patients with advanced pancreatic ductal adenocarcinoma, a single centre cohort study. Thromb J 2020;18:9. [PMID: 32514256 DOI: 10.1186/s12959-020-00222-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
435 Parente P, Parcesepe P, Covelli C, Olivieri N, Remo A, Pancione M, Latiano TP, Graziano P, Maiello E, Giordano G. Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches. Gastroenterol Res Pract. 2018;2018:7530619. [PMID: 30662458 DOI: 10.1155/2018/7530619] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
436 Wu AA, Jaffee E, Lee V. Current Status of Immunotherapies for Treating Pancreatic Cancer. Curr Oncol Rep 2019;21:60. [PMID: 31101991 DOI: 10.1007/s11912-019-0811-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
437 Zhang L, Tong Y, Zhang X, Pan M, Chen S. Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth. Drug Des Devel Ther 2015;9:5851-62. [PMID: 26586936 DOI: 10.2147/DDDT.S92943] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
438 Ghosn M, Ibrahim T, Assi T, El Rassy E, Kourie HR, Kattan J. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(46): 10124-10130 [PMID: 28028360 DOI: 10.3748/wjg.v22.i46.10124] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
439 Jun E, Song AY, Choi JW, Lee HH, Kim MY, Ko DH, Kang HJ, Kim SW, Bryceson Y, Kim SC, Kim HS. Progressive Impairment of NK Cell Cytotoxic Degranulation Is Associated With TGF-β1 Deregulation and Disease Progression in Pancreatic Cancer. Front Immunol 2019;10:1354. [PMID: 31281312 DOI: 10.3389/fimmu.2019.01354] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
440 Dallos MC, Eisenberger AB, Bates SE. Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma. Oncologist 2020;25:132-9. [PMID: 32043768 DOI: 10.1634/theoncologist.2019-0264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
441 Kauffmann EF, Napoli N, Menonna F, Vistoli F, Amorese G, Campani D, Pollina LE, Funel N, Cappelli C, Caramella D, Boggi U. Robotic pancreatoduodenectomy with vascular resection. Langenbecks Arch Surg. 2016;401:1111-1122. [PMID: 27553112 DOI: 10.1007/s00423-016-1499-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
442 Luu AM, Hoehn P, Vogel SR, Reinacher-Schick A, Munding J, Uhl W, Braumann C. Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer. Visc Med 2019;35:387-91. [PMID: 31934588 DOI: 10.1159/000497827] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
443 Kyrochristos ID, Glantzounis GK, Ziogas DE, Gizas I, Schizas D, Lykoudis EG, Felekouras E, Machairas A, Katsios C, Liakakos T, Cho WC, Roukos DH. From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci 2017;18:E180. [PMID: 28106782 DOI: 10.3390/ijms18010180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
444 Abánades Lázaro I, Wells CJR, Forgan RS. Multivariate Modulation of the Zr MOF UiO-66 for Defect-Controlled Combination Anticancer Drug Delivery. Angew Chem Int Ed Engl 2020;59:5211-7. [PMID: 31950568 DOI: 10.1002/anie.201915848] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 26.5] [Reference Citation Analysis]
445 Roth MT, Cardin DB, Berlin JD. Recent advances in the treatment of pancreatic cancer. F1000Res. 2020;9. [PMID: 32148767 DOI: 10.12688/f1000research.21981.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
446 Azemoto N, Ueno M, Yanagimoto H, Mizuno N, Kawamoto Y, Maruki Y, Watanabe K, Suzuki R, Kaneko J, Hisada Y, Sato H, Kobayashi S, Miyata H, Furukawa M, Mizukami T, Miwa H, Ohno Y, Tsuji K, Tsujimoto A, Nagano H, Okuyama H, Asagi A, Okano N, Ishii H, Morizane C, Ikeda M, Furuse J. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial chemotherapy (GASPACHO study): a multicenter retrospective study. Jpn J Clin Oncol 2022;52:134-42. [PMID: 34969090 DOI: 10.1093/jjco/hyab194] [Reference Citation Analysis]
447 Hua J, Shi S, Liang D, Liang C, Meng Q, Zhang B, Ni Q, Xu J, Yu X. Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining? Onco Targets Ther 2018;11:4591-608. [PMID: 30122951 DOI: 10.2147/OTT.S166405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
448 Kang S, Lee S, Park S. iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery. Polymers (Basel) 2020;12:E1906. [PMID: 32847045 DOI: 10.3390/polym12091906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
449 Kang H. Efficacy of Adjuvant Chemotherapy after Neoadjuvant FOLFIRINOX and Following Resection of Pancreatic Cancer. Korean J Gastroenterol 2021;77:95-6. [DOI: 10.4166/kjg.2021.016] [Reference Citation Analysis]
450 Javadrashid D, Baghbanzadeh A, Derakhshani A, Leone P, Silvestris N, Racanelli V, Solimando AG, Baradaran B. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines 2021;9:373. [PMID: 33918146 DOI: 10.3390/biomedicines9040373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
451 Maier-Stocker C, Bitzer M, Malek NP, Plentz RR. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort. Scand J Gastroenterol 2014;49:1480-5. [PMID: 25390691 DOI: 10.3109/00365521.2014.978816] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
452 Moser C, Ruemmele P, Gehmert S, Schenk H, Kreutz MP, Mycielska ME, Hackl C, Kroemer A, Schnitzbauer AA, Stoeltzing O, Schlitt HJ, Geissler EK, Lang SA. STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases. Neoplasia 2012;14:915-25. [PMID: 23097626 DOI: 10.1593/neo.12878] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
453 Domadia K, Goel V, Koyyala VPB, Patnaik N, Chaudhari K, Raina S, Doval DC, Talwar V. Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma. South Asian J Cancer. [DOI: 10.1055/s-0041-1735956] [Reference Citation Analysis]
454 Ali EM, Maklad AM, Khallaf SM. Prolonged Infusion of Low Dose Gemcitabine in Advanced Pancreatic Carcinoma. JCT 2020;11:401-9. [DOI: 10.4236/jct.2020.117035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
455 Anbil S, Pigula M, Huang HC, Mallidi S, Broekgaarden M, Baglo Y, De Silva P, Simeone DM, Mino-Kenudson M, Maytin EV, Rizvi I, Hasan T. Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy. Mol Cancer Ther 2020;19:1308-19. [PMID: 32220968 DOI: 10.1158/1535-7163.MCT-19-0791] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
456 Kim EJ, Kim YJ, Lee HI, Jeong SH, Nam HJ, Cho JH. NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression. Int J Mol Sci 2020;21:E4646. [PMID: 32629871 DOI: 10.3390/ijms21134646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
457 Iovanna J. Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. Transl Oncol 2021;14:100965. [PMID: 33248412 DOI: 10.1016/j.tranon.2020.100965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
458 Wang H, Ding W, Shi H, Bao H, Lu Y, Jiang TA. Combination therapy with low-frequency ultrasound irradiation and radiofrequency ablation as a synergistic treatment for pancreatic cancer. Bioengineered 2021. [PMID: 34696663 DOI: 10.1080/21655979.2021.1995581] [Reference Citation Analysis]
459 Peng C, Xu B, Xiao J, Zhou C, Li X, Shi H, Qiang W, Wang T, Zhao J, Liu F, Li G, Li H, Chen C, Shi L. Hepatic Artery Infusion of Floxuridine in Combination With Systemic Chemotherapy for Pancreatic Cancer Liver Metastasis: A Propensity Score-Matched Analysis in Two Centers. Front Oncol 2021;11:652426. [PMID: 33996572 DOI: 10.3389/fonc.2021.652426] [Reference Citation Analysis]
460 Furuse J. Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan. J Clin Med 2019;8:E1170. [PMID: 31382681 DOI: 10.3390/jcm8081170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
461 Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, Parkinson RM, Durham JN, Onners B, Ferguson AK, Wilt C, Ko AH, Wang-Gillam A, Laheru DA, Anders RA, Thompson ED, Sugar EA, Jaffee EM, Le DT. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Clin Cancer Res. 2020;26:5129-5139. [PMID: 32591464 DOI: 10.1158/1078-0432.ccr-20-1025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
462 Krell J, Frampton AE, Jiao LR, Stebbing J. Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma? Pharmacogenomics 2012;13:977-9. [PMID: 22838942 DOI: 10.2217/pgs.12.73] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
463 Eto K, Kawakami H, Kuwatani M, Kudo T, Abe Y, Kawahata S, Takasawa A, Fukuoka M, Matsuno Y, Asaka M, Sakamoto N. Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer. Br J Cancer 2013;108:1488-94. [PMID: 23492684 DOI: 10.1038/bjc.2013.108] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
464 Glassman DC, Palmaira RL, Covington CM, Desai AM, Ku GY, Li J, Harding JJ, Varghese AM, O'Reilly EM, Yu KH. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC Cancer 2018;18:693. [PMID: 29945562 DOI: 10.1186/s12885-018-4605-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
465 Pelzer U, Hilbig A, Stieler JM, Bahra M, Sinn M, Gebauer B, Dörken B, Riess H. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer 2014;14:204. [PMID: 24641937 DOI: 10.1186/1471-2407-14-204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
466 Vorobyov N, Rykov I, Orlova R, Cherkashin M. Chemotherapy in combination with stereotactic body radiation therapy (SBRT) for oligometastatic pancreatic cancer. BMJ Case Rep 2018;2018:bcr-2018-225846. [PMID: 30219780 DOI: 10.1136/bcr-2018-225846] [Reference Citation Analysis]
467 Garrido-Laguna I, Tometich D, Hu N, Ying J, Geiersbach K, Whisenant J, Wang K, Ross JS, Sharma S. N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience 2015;2:285-93. [PMID: 25897431 DOI: 10.18632/oncoscience.141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
468 Haj Mohammad N, Bernards N, Besselink MG, Busch OR, Wilmink JW, Creemers GJ, De Hingh IH, Lemmens VE, van Laarhoven HW. Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands. J Cancer Res Clin Oncol 2016;142:1353-60. [PMID: 26995276 DOI: 10.1007/s00432-016-2140-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
469 Adenis A, Mazard T, Fraisse J, Chalbos P, Pastor B, Evesque L, Ghiringhelli F, Mollevi C, Delaine S, Ychou M. FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer. BMC Cancer 2021;21:564. [PMID: 34001059 DOI: 10.1186/s12885-021-08312-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
470 Deodhar S, Dash AK, North EJ, Hulce M. Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma. AAPS PharmSciTech 2020;21:231. [PMID: 32778980 DOI: 10.1208/s12249-020-01745-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
471 Yuan K, Yong S, Xu F, Zhou T, McDonald JM, Chen Y. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer. Oncotarget 2015;6:25308-19. [PMID: 26320171 DOI: 10.18632/oncotarget.4490] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
472 Sperti C, Moletta L, Merigliano S. Multimodality treatment of recurrent pancreatic cancer: Mith or reality? World J Gastrointest Oncol 2015; 7(12): 375-382 [PMID: 26689800 DOI: 10.4251/wjgo.v7.i12.375] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
473 Kruger S, Schirle K, Haas M, Crispin A, Schirra J, Mayerle J, D'Haese JG, Kunz WG, Ricke J, Ormanns S, Kirchner T, Kobold S, Ilmer M, Gebauer L, Westphalen CB, von Bergwelt-Baildon M, Werner J, Heinemann V, Boeck S. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox. J Cancer Res Clin Oncol 2020;146:391-9. [PMID: 31642961 DOI: 10.1007/s00432-019-03061-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
474 Kandimalla R, Tomihara H, Banwait JK, Yamamura K, Singh G, Baba H, Goel A. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26:3641-8. [PMID: 32234757 DOI: 10.1158/1078-0432.CCR-19-4044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
475 Sharbeen G, McCarroll J, Liu J, Youkhana J, Limbri LF, Biankin AV, Johns A, Kavallaris M, Goldstein D, Phillips PA. Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids. Neoplasia 2016;18:753-64. [PMID: 27889644 DOI: 10.1016/j.neo.2016.10.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
476 Sarr A, Bré J, Um IH, Chan TH, Mullen P, Harrison DJ, Reynolds PA. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031. Sci Rep 2019;9:7643. [PMID: 31113993 DOI: 10.1038/s41598-019-44089-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
477 Pandey V, Storz P. Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma. Expert Rev Anticancer Ther 2019;19:473-82. [PMID: 31148495 DOI: 10.1080/14737140.2019.1622417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
478 Shen F, Liu C, Zhang W, He S, Wang F, Wang J, Li Q, Zhou F. Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer. Front Oncol 2022;12:964115. [DOI: 10.3389/fonc.2022.964115] [Reference Citation Analysis]
479 Smiley K, Malhotra R, Peche W, Langell JT. Unresectable Pancreatic Adenocarcinoma: Eight Years Later. World J Oncol 2016;7:17-20. [PMID: 28983358 DOI: 10.14740/wjon957w] [Reference Citation Analysis]
480 Elshami M, Ahmed FA, Kakish H, Hue JJ, Hoehn RS, Rothermel LD, Bajor D, Mohamed A, Selfridge J, Ammori JB, Hardacre JM, Winter JM, Ocuin LM. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. HPB 2022. [DOI: 10.1016/j.hpb.2022.07.007] [Reference Citation Analysis]
481 Murphy KJ, Chambers CR, Herrmann D, Timpson P, Pereira BA. Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. Cancers (Basel) 2021;13:3481. [PMID: 34298706 DOI: 10.3390/cancers13143481] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
482 Palagani V, El Khatib M, Kossatz U, Bozko P, Müller MR, Manns MP, Krech T, Malek NP, Plentz RR. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX. PLoS One. 2012;7:e46514. [PMID: 23094026 DOI: 10.1371/journal.pone.0046514] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
483 Yamao K, Takenaka M, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Kamata K, Minaga K, Hagiwara S, Sakurai T, Nishida N, Chiba Y, Watanabe T, Kudo M. Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study. Intern Med 2019;58:1993-2002. [PMID: 30996164 DOI: 10.2169/internalmedicine.2234-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
484 Akhoundova Sanoyan D, Reiner CS, Papageorgiou P, Siebenhüner AR. Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line. Case Rep Oncol 2020;13:79-84. [PMID: 32110224 DOI: 10.1159/000504471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
485 Hassanzadeh C, Rudra S, Bommireddy A, Hawkins WG, Wang-Gillam A, Fields RC, Cai B, Park J, Green O, Roach M, Henke L, Kim H. Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Adv Radiat Oncol 2021;6:100506. [PMID: 33665480 DOI: 10.1016/j.adro.2020.06.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
486 Ye LF, Ren C, Bai L, Liang JY, Hu MT, Yang H, Wang ZQ, Wang FH, Xu RH, Li YH, Wang DS. Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study. Invest New Drugs 2021;39:836-45. [PMID: 33411209 DOI: 10.1007/s10637-020-01045-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
487 Mancini BR, Stein S, Lloyd S, Rutter CE, James E, Chang BW, Lacy J, Johung KL. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. J Gastrointest Oncol 2018;9:982-8. [PMID: 30603116 DOI: 10.21037/jgo.2018.04.03] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
488 Wang Y, Lakoma A, Zogopoulos G. Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Genes (Basel) 2020;11:E1098. [PMID: 32967105 DOI: 10.3390/genes11091098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
489 Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D'Angelica MI, Endo I, Parks RW, Doyle M, de Santibañes E, Pawlik TM. Liver metastases. Nat Rev Dis Primers 2021;7:27. [PMID: 33859205 DOI: 10.1038/s41572-021-00261-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
490 Wang HC, Hung WC, Chen LT, Pan MR. From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. Int J Mol Sci 2018;19:E3584. [PMID: 30428588 DOI: 10.3390/ijms19113584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
491 Ikezawa K, Kiyota R, Takada R, Daiku K, Maeda S, Imai T, Abe Y, Kai Y, Yamai T, Fukutake N, Nakabori T, Ashida R, Uehara H, Tabuchi T, Katayama K, Ohkawa K. Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer. JGH Open 2021;5:679-85. [PMID: 34124386 DOI: 10.1002/jgh3.12555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
492 Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol 2017;18:770-8. [PMID: 28495639 DOI: 10.1016/S1470-2045(17)30314-5] [Cited by in Crossref: 91] [Cited by in F6Publishing: 66] [Article Influence: 18.2] [Reference Citation Analysis]
493 Gu M, Gao Y, Chang P. KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas. Cancers (Basel) 2021;13:2429. [PMID: 34069772 DOI: 10.3390/cancers13102429] [Reference Citation Analysis]
494 Itonaga M, Ashida R, Murata S, Yamashita Y, Hatamaru K, Tamura T, Kawaji Y, Kayama Y, Emori T, Kawai M, Yamaue H, Matsuzaki I, Nagai H, Kinoshita Y, Wan K, Shimokawa T, Kitano M. Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer. Cancers 2022;14:551. [DOI: 10.3390/cancers14030551] [Reference Citation Analysis]
495 Hashim YM, Vangveravong S, Sankpal NV, Binder PS, Liu J, Goedegebuure SP, Mach RH, Spitzer D, Hawkins WG. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. J Exp Clin Cancer Res 2017;36:14. [PMID: 28095907 DOI: 10.1186/s13046-016-0470-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
496 Cardin DB, Goff LW, Chan E, Whisenant JG, Dan Ayers G, Takebe N, Arlinghaus LR, Yankeelov TE, Berlin J, Merchant N. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 2018;36:442-50. [PMID: 28990119 DOI: 10.1007/s10637-017-0519-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
497 Zhang K, Dong S, Jing YH, Gao HF, Chen LY, Hua YQ, Chen H, Chen Z. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis. BMC Cancer 2020;20:541. [PMID: 32517802 DOI: 10.1186/s12885-020-07023-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
498 Perkail S, Andricovich J, Kai Y, Tzatsos A. BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice. Nat Commun 2020;11:3018. [PMID: 32541668 DOI: 10.1038/s41467-020-16589-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
499 Fru PN, Nweke EE, Mthimkhulu N, Mvango S, Nel M, Pilcher LA, Balogun M. Anti-Cancer and Immunomodulatory Activity of a Polyethylene Glycol-Betulinic Acid Conjugate on Pancreatic Cancer Cells. Life (Basel) 2021;11:462. [PMID: 34063891 DOI: 10.3390/life11060462] [Reference Citation Analysis]
500 Abali H, Sezer A, Oğuzkurt L, Gürel K, Özkan U, Beşen AA, Sümbül AT, Köse F, Dişel U, Muallaoğlu S, Özyılkan Ö. Which patients with advanced cancer and biliary obstruction benefit from biliary stenting most? An analysis of prognostic factors. Support Care Cancer 2013;21:1131-5. [PMID: 23132146 DOI: 10.1007/s00520-012-1636-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
501 Mavros MN, Coburn NG, Davis LE, Mahar AL, Liu Y, Beyfuss K, Myrehaug S, Earle CC, Hallet J. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. CMAJ 2019;191:E574-80. [PMID: 31133604 DOI: 10.1503/cmaj.190211] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
502 Ma J, Duan W, Han S, Lei J, Xu Q, Chen X, Jiang Z, Nan L, Li J, Chen K, Han L, Wang Z, Li X, Wu E, Huo X. Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis. Oncotarget 2015;6:20993-1003. [PMID: 25895130 DOI: 10.18632/oncotarget.3663] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
503 Cui J, Yang H, Liu J, Chen D, Hu J, Zhang H, Wang Y, Han T, Mao T, Jiao F, Biskup E, Pan Y, Liu M, Wang L. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer 2021;21:672. [PMID: 34098895 DOI: 10.1186/s12885-021-08375-6] [Reference Citation Analysis]
504 Vera R, Dotor E, Feliu J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Clin Transl Oncol 2016;18:1172-8. [PMID: 27896637 DOI: 10.1007/s12094-016-1586-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
505 Khan MA, Srivastava SK, Zubair H, Patel GK, Arora S, Khushman M, Carter JE, Gorman GS, Singh S, Singh AP. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer. J Biol Chem 2020;295:8413-24. [PMID: 32358063 DOI: 10.1074/jbc.RA119.011748] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
506 Hamada T, Yuan C, Bao Y, Zhang M, Khalaf N, Babic A, Morales-Oyarvide V, Cochrane BB, Gaziano JM, Giovannucci EL, Kraft P, Manson JE, Ng K, Nowak JA, Rohan TE, Sesso HD, Stampfer MJ, Amundadottir LT, Fuchs CS, De Vivo I, Ogino S, Wolpin BM. Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Cancer Epidemiol Biomarkers Prev 2019;28:1868-75. [PMID: 31427306 DOI: 10.1158/1055-9965.EPI-19-0577] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
507 Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, Khazak V, Jablonski SA, Golemis EA, Weiner LM, Astsaturov I. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer. Clin Cancer Res 2016;22:6153-63. [PMID: 27384421 DOI: 10.1158/1078-0432.CCR-16-0149] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
508 Zhang X, Detering L, Sultan D, Luehmann H, Li L, Heo GS, Zhang X, Lou L, Grierson PM, Greco S, Ruzinova M, Laforest R, Dehdashti F, Lim KH, Liu Y. CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. ACS Nano 2021;15:1186-98. [PMID: 33406361 DOI: 10.1021/acsnano.0c08185] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
509 Oh D, Pyo JS, Son BK. Prognostic Roles of Inflammatory Markers in Pancreatic Cancer: Comparison between the Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. Gastroenterol Res Pract 2018;2018:9745601. [PMID: 29977290 DOI: 10.1155/2018/9745601] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
510 Li M, Yu X, Guo H, Sun L, Wang A, Liu Q, Wang X, Li J. Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells. Tumour Biol. 2014;35:2461-2471. [PMID: 24218335 DOI: 10.1007/s13227-013-1326-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
511 Emelyanova M, Pudova E, Khomich D, Krasnov G, Popova A, Abramov I, Mikhailovich V, Filipenko M, Menshikova S, Tjulandin S, Pokataev I. Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes. Ther Adv Med Oncol 2022;14:175883592210830. [DOI: 10.1177/17588359221083050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
512 Rochefort P, Lardy-Cleaud A, Sarabi M, Desseigne F, Cattey-Javouhey A, de la Fouchardière C. Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis. Oncologist 2019;24:1543-8. [PMID: 31164454 DOI: 10.1634/theoncologist.2018-0786] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
513 Yuan C, Qian ZR, Babic A, Morales-Oyarvide V, Rubinson DA, Kraft P, Ng K, Bao Y, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Sesso HD, Buring JE, Cochrane BB, Chlebowski RT, Snetselaar LG, Manson JE, Fuchs CS, Wolpin BM. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. J Clin Oncol. 2016;34:2899-2905. [PMID: 27325858 DOI: 10.1200/jco.2015.66.3005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
514 Forero-Torres A, Infante JR, Waterhouse D, Wong L, Vickers S, Arrowsmith E, He AR, Hart L, Trent D, Wade J, Jin X, Wang Q, Austin T, Rosen M, Beckman R, von Roemeling R, Greenberg J, Saleh M. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer. Cancer Med 2013;2:925-32. [PMID: 24403266 DOI: 10.1002/cam4.137] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 6.4] [Reference Citation Analysis]
515 Krepline AN, Bliss L, Geurts J, Akinola I, Christians KK, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? J Gastrointest Surg 2020;24:235-42. [DOI: 10.1007/s11605-019-04423-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
516 Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. J Gastrointest Oncol 2017;8:925-35. [PMID: 29299351 DOI: 10.21037/jgo.2017.09.05] [Reference Citation Analysis]
517 Yu KH, Park J, Mittal A, Abou-Alfa GK, El Dika I, Epstein AS, Ilson DH, Kelsen DP, Ku GY, Li J, Park W, Varghese AM, Chou JF, Capanu M, Cooper B, Bartlett A, McCarthy D, Sangar V, McCarthy B, O'Reilly EM. Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Cancer 2022. [PMID: 35647938 DOI: 10.1002/cncr.34269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
518 Qin R, Smyrk TC, Reed NR, Schmidt RL, Schnelldorfer T, Chari ST, Petersen GM, Tang AH. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer. Br J Cancer 2015;112:514-22. [PMID: 25584484 DOI: 10.1038/bjc.2014.659] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
519 Le Calvé B, Griveau A, Vindrieux D, Maréchal R, Wiel C, Svrcek M, Gout J, Azzi L, Payen L, Cros J, de la Fouchardière C, Dubus P, Guitton J, Bartholin L, Bachet JB, Bernard D. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution. Oncotarget 2016;7:32100-12. [PMID: 27050073 DOI: 10.18632/oncotarget.8527] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
520 Moravec R, Divi R, Verma M. Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World J Gastrointest Oncol 2017; 9(6): 235-250 [PMID: 28656074 DOI: 10.4251/wjgo.v9.i6.235] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
521 Bai Z, Shi Y, Wang J, Qiu L, Monroe EJ, Teng G, Zhang F, Yang X. Intratumoral radiofrequency hyperthermia-enhanced direct chemotherapy of pancreatic cancer. Oncotarget 2017;8:3591-9. [PMID: 27690303 DOI: 10.18632/oncotarget.12295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
522 Zanini N, Lombardi R, Masetti M, Giordano M, Landolfo G, Jovine E. Surgery for isolated liver metastases from pancreatic cancer. Updates Surg. 2015;67:19-25. [PMID: 25702263 DOI: 10.1007/s13304-015-0283-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
523 El Haddaoui H, Brood R, Latifi D, Oostvogels AA, Klaver Y, Moskie M, Mustafa DA, Debets R, van Eijck CHJ. Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program. Cancers (Basel) 2022;14:1377. [PMID: 35326528 DOI: 10.3390/cancers14061377] [Reference Citation Analysis]
524 Malkoç E, Aktaş Z, Kara K, Haholu A. Renal metastasis from pancreatic adenocarcinoma: a rare case along with literature review. Turk J Urol 2015;41:93-5. [PMID: 26328209 DOI: 10.5152/tud.2015.54280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
525 Zhao L, Liu Y, Zhao F, Jin Y, Feng J, Geng R, Sun J, Kang L, Yu L, Wei Y. Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma. Mol Ther Oncolytics 2020;16:262-71. [PMID: 32181327 DOI: 10.1016/j.omto.2020.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
526 Argentiero A, Calabrese A, Solimando AG, Notaristefano A, Panarelli MMG, Brunetti O. Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review. Clin Case Rep 2019;7:1972-6. [PMID: 31624620 DOI: 10.1002/ccr3.2412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
527 Nakamura T, Katagiri T, Sato S, Kushibiki T, Hontani K, Tsuchikawa T, Hirano S, Nakamura Y. Overexpression of C16orf74 is involved in aggressive pancreatic cancers. Oncotarget 2017;8:50460-75. [PMID: 28881575 DOI: 10.18632/oncotarget.10912] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
528 Patel K, Kollory A, Takashima A, Sarkar S, Faller DV, Ghosh SK. MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression. Cancer Lett. 2014;347:54-64. [PMID: 24491408 DOI: 10.1016/j.canlet.2014.01.020] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
529 Timmer FEF, Geboers B, Nieuwenhuizen S, Schouten EAC, Dijkstra M, de Vries JJJ, van den Tol MP, Meijerink MR, Scheffer HJ. Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review. Cancers (Basel) 2021;13:1608. [PMID: 33807220 DOI: 10.3390/cancers13071608] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
530 Latenstein AEJ, Mackay TM, Creemers GJ, van Eijck CHJ, de Groot JWB, Haj Mohammad N, Homs MYV, van Laarhoven HWM, Molenaar IQ, Ten Tije BJ, de Vos-Geelen J, Besselink MG, van der Geest LGM, Wilmink JW; Dutch Pancreatic Cancer Group. Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. Acta Oncol 2020;59:705-12. [PMID: 32056483 DOI: 10.1080/0284186X.2020.1725241] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
531 Lee M, Kang JS, Kim H, Kwon W, Lee SH, Ryu JK, Kim YT, Oh DY, Chie EK, Jang JY. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. J Hepatobiliary Pancreat Sci 2021. [PMID: 34581022 DOI: 10.1002/jhbp.1050] [Reference Citation Analysis]
532 Schneitler S, Kröpil P, Riemer J, Antoch G, Knoefel WT, Häussinger D, Graf D. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection. World J Gastroenterol 2015; 21(20): 6384-6390 [PMID: 26034375 DOI: 10.3748/wjg.v21.i20.6384] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
533 Dagoglu N, Callery M, Moser J, Tseng J, Kent T, Bullock A, Miksad R, Mancias JD, Mahadevan A. Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer. J Cancer 2016;7:283-8. [PMID: 26918041 DOI: 10.7150/jca.13295] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
534 Serrano PE, Herman JM, Griffith KA, Zalupski MM, Kim EJ, Bekaii-Saab TS, Ben-Josef E, Dawson LA, Ringash J, Wei AC. Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2014;90:270-7. [PMID: 25104069 DOI: 10.1016/j.ijrobp.2014.05.053] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
535 Gayral M, Lulka H, Hanoun N, Biollay C, Sèlves J, Vignolle-Vidoni A, Berthommé H, Trempat P, Epstein AL, Buscail L, Béjot JL, Cordelier P. Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors. Hum Gene Ther 2015;26:104-13. [PMID: 25423447 DOI: 10.1089/hum.2014.072] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
536 Du J, Gu J, Li J. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Biosci Rep 2020;40:BSR20200401. [PMID: 32677676 DOI: 10.1042/BSR20200401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
537 Haller SD, Monaco ML, Essani K. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer. Viruses. 2020;12. [PMID: 33213031 DOI: 10.3390/v12111318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
538 Mitsuka Y, Yamazaki S, Yoshida N, Yan M, Higaki T, Takayama T. Time interval-based indication for liver resection of metastasis from pancreatic cancer. World J Surg Oncol 2020;18:294. [PMID: 33172482 DOI: 10.1186/s12957-020-02058-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
539 Roger E, Gout J, Arnold F, Beutel AK, Müller M, Abaei A, Barth TFE, Rasche V, Seufferlein T, Perkhofer L, Kleger A. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. Cells 2020;9:E2110. [PMID: 32948057 DOI: 10.3390/cells9092110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
540 Borazanci E, Pishvaian MJ, Nemunaitis J, Weekes C, Huang J, Rajakumaraswamy N. A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Oncologist 2020;25:e1604-13. [PMID: 32356383 DOI: 10.1634/theoncologist.2020-0321] [Reference Citation Analysis]
541 Murakawa Y, Ootsuka K, Abue M. The Appropriate First-Line Chemotherapy Regimen for Incurable Pancreatic Cancer in Clinical Practice: A Consideration of Patients' Overall Survival and Quality of Life. J Pancreat Cancer 2021;7:48-56. [PMID: 34901695 DOI: 10.1089/pancan.2021.0005] [Reference Citation Analysis]
542 Li D, Mullinax JE, Aiken T, Xin H, Wiegand G, Anderson A, Thorgeirsson S, Avital I, Rudloff U. Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells. BMC Cancer 2018;18:772. [PMID: 30064387 DOI: 10.1186/s12885-018-4690-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
543 Crippa S, Cirocchi R, Weiss MJ, Partelli S, Reni M, Wolfgang CL, Hackert T, Falconi M. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg 2020;72:39-45. [PMID: 31997233 DOI: 10.1007/s13304-020-00710-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
544 Chllamma MK, Cook N, Dhani NC, Giby K, Dodd A, Wang L, Hedley DW, Moore MJ, Knox JJ. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Br J Cancer. 2016;115:649-654. [PMID: 27467054 DOI: 10.1038/bjc.2016.222] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
545 Yu X, Di Y, Xie C, Song Y, He H, Li H, Pu X, Lu W, Fu D, Jin C. An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line. Int J Nanomedicine 2015;10:6825-34. [PMID: 26586944 DOI: 10.2147/IJN.S93835] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
546 Lahoud MJ, Kourie HR, Antoun J, El Osta L, Ghosn M. Road map for pain management in pancreatic cancer: A review. World J Gastrointest Oncol 2016; 8(8): 599-606 [PMID: 27574552 DOI: 10.4251/wjgo.v8.i8.599] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
547 Hegewisch-Becker S, Aldaoud A, Wolf T, Krammer-Steiner B, Linde H, Scheiner-Sparna R, Hamm D, Jänicke M, Marschner N; TPK-Group (Tumour Registry Pancreatic Cancer). Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. Int J Cancer 2019;144:981-90. [PMID: 30006989 DOI: 10.1002/ijc.31751] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
548 Ma YT, Leonard SM, Gordon N, Anderton J, James C, Huen D, Woodman CB, Palmer DH. Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer. Oncotarget 2017;8:63635-45. [PMID: 28969017 DOI: 10.18632/oncotarget.18879] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
549 Li Y, Liu W, Zhao L, Xu Y, Yan T, Yang Q, Pei Q, Güngör C. The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis. Med Sci Monit 2020;26:e921515. [PMID: 32358953 DOI: 10.12659/MSM.921515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
550 Stonko DP, He J, Zheng L, Blair AB. A contemporary evidence basis for neoadjuvant chemotherapy in upfront resectable pancreatic adenocarcinoma: a systematic review of the literature. Journal of Pancreatology 2020;3:12-20. [DOI: 10.1097/jp9.0000000000000037] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
551 Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World J Gastrointest Oncol 2016; 8(3): 248-257 [PMID: 26989460 DOI: 10.4251/wjgo.v8.i3.248] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
552 Dai WF, Beca J, Guo H, Isaranawatchai W, Schwartz D, Naipaul R, Arias J, Qiao Y, Gavura S, Redmond-Misner R, Ismail Z, Barbera L, Chan K. Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer? Cancer Med 2020;9:215-24. [PMID: 31736256 DOI: 10.1002/cam4.2704] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
553 Hermann PC, Trabulo SM, Sainz B Jr, Balic A, Garcia E, Hahn SA, Vandana M, Sahoo SK, Tunici P, Bakker A. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. PLoS One. 2013;8:e66371. [PMID: 23825539 DOI: 10.1371/journal.pone.0066371] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
554 Yagyu T, Ohira T, Shimizu R, Morimoto M, Murakami Y, Hanaki T, Kihara K, Matsunaga T, Yamamoto M, Tokuyasu N, Sakamoto T, Fujiwara Y, Kugoh H. Human chromosome 3p21.3 carries TERT transcriptional regulators in pancreatic cancer. Sci Rep 2021;11:15355. [PMID: 34321527 DOI: 10.1038/s41598-021-94711-6] [Reference Citation Analysis]
555 Vena F, Bayle S, Nieto A, Quereda V, Aceti M, Frydman SM, Sansil SS, Grant W, Monastyrskyi A, McDonald P, Roush WR, Teng M, Duckett D. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase. Mol Cancer Ther. 2020;19:1623-1635. [PMID: 32430484 DOI: 10.1158/1535-7163.mct-19-0997] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
556 Zhao T, Ren H, Jia L, Chen J, Xin W, Yan F, Li J, Wang X, Gao S, Qian D. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget. 2015;6:2250-2262. [PMID: 25544770 DOI: 10.18632/oncotarget.2948] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 10.2] [Reference Citation Analysis]
557 Imai H, Saijo K, Komine K, Yoshida Y, Sasaki K, Suzuki A, Ouchi K, Takahashi M, Takahashi S, Shirota H, Takahashi M, Ishioka C. Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients. J Oncol 2020;2020:1701326. [PMID: 32655636 DOI: 10.1155/2020/1701326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
558 Braghiroli MI, de Celis Ferrari AC, Pfiffer TE, Alex AK, Nebuloni D, Carneiro AS, Caparelli F, Senna L, Lobo J, Hoff PM, Riechelmann RP. Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. Ecancermedicalscience. 2015;9:563. [PMID: 26316884 DOI: 10.3332/ecancer.2015.563] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
559 Perez VM, Kearney JF, Yeh JJ. The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies. Front Oncol 2021;11:751311. [PMID: 34692532 DOI: 10.3389/fonc.2021.751311] [Reference Citation Analysis]
560 Fotopoulos G, Syrigos K, Saif MW. Genetic factors affecting patient responses to pancreatic cancer treatment. Ann Gastroenterol 2016;29:466-76. [PMID: 27708512 DOI: 10.20524/aog.2016.0056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
561 Park JH, Jo JH, Jang SI, Chung MJ, Park JY, Bang S, Park SW, Song SY, Lee HS, Cho JH. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. Cancers (Basel) 2022;14:236. [PMID: 35008403 DOI: 10.3390/cancers14010236] [Reference Citation Analysis]
562 Wang Z, Liu Y, Li R, Shang Y, Zhang Y, Zhao L, Li W, Yang Y, Zhang X, Yang T, Nie C, Han F, Luo S, Gao Q, Song Y. Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer. J Hematol Oncol. 2016;9:6. [PMID: 26842696 DOI: 10.1186/s13045-016-0237-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
563 Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine (Lond) 2019;14:93-126. [PMID: 30451076 DOI: 10.2217/nnm-2018-0120] [Cited by in Crossref: 143] [Cited by in F6Publishing: 100] [Article Influence: 35.8] [Reference Citation Analysis]
564 McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Hum Vaccin Immunother 2016;12:563-75. [PMID: 26619245 DOI: 10.1080/21645515.2015.1093264] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
565 Heestand GM, Kurzrock R. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget 2015;6:4553-61. [PMID: 25714017 DOI: 10.18632/oncotarget.2972] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 8.5] [Reference Citation Analysis]
566 Kobayashi Y, Maeda S, Hama N, Miyamoto A, Uemura M, Miyake M, Nishikawa K, Hirao M, Kato T, Sekimoto M, Mori K, Mano M, Nakamori S. Successful conversion surgery for unresectable pancreatic cancer with peritoneal metastases after neoadjuvant albumin-bound paclitaxel and gemcitabine chemotherapy: case report and literature review. Int Cancer Conf J 2018;7:20-5. [PMID: 31149507 DOI: 10.1007/s13691-017-0311-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
567 Liu Y, Awadia S, Delaney A, Sitto M, Engelke CG, Patel H, Calcaterra A, Zelenka-Wang S, Lee H, Contessa J, Neamati N, Ljungman M, Lawrence TS, Morgan MA, Rehemtulla A. UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer. Transl Oncol 2020;13:100834. [PMID: 32688248 DOI: 10.1016/j.tranon.2020.100834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
568 Takagi K, Yagi T, Umeda Y, Yoshida R, Nobuoka D, Kuise T, Kumano K, Kojima T, Fushimi T, Fujiwara T. A novel intestinal rotation method for digestive reconstruction after combined pancreaticoduodenectomy and extended right hemicolectomy: A case report and surgical technique. Int J Surg Case Rep 2017;39:51-5. [PMID: 28806620 DOI: 10.1016/j.ijscr.2017.07.063] [Reference Citation Analysis]
569 Witkiewicz AK, Borja NA, Franco J, Brody JR, Yeo CJ, Mansour J, Choti MA, McCue P, Knudsen ES. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget 2015;6:15788-801. [PMID: 26158861 DOI: 10.18632/oncotarget.3819] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
570 Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. J Gastrointest Cancer 2013;44:182-9. [PMID: 23208490 DOI: 10.1007/s12029-012-9466-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
571 Yang SH, Kuo TC, Wu H, Guo JC, Hsu C, Hsu CH, Tien YW, Yeh KH, Cheng AL, Kuo SH. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World J Gastroenterol 2016; 22(32): 7275-7288 [PMID: 27621574 DOI: 10.3748/wjg.v22.i32.7275] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
572 Søreide K, Primavesi F, Labori KJ, Watson MM, Stättner S. Molecular biology in pancreatic ductal adenocarcinoma: implications for future diagnostics and therapy. Eur Surg 2019;51:126-34. [DOI: 10.1007/s10353-019-0575-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
573 Pelzer U, Sinn M, Stieler J, Riess H. [Multimodal treatment of pancreatic cancer]. Internist (Berl). 2014;55:31-36. [PMID: 24399472 DOI: 10.1007/s00108-013-3316-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
574 Tesfaye AA, Wang H, Hartley ML, He AR, Weiner L, Gabelia N, Kapanadze L, Shezad M, Brody JR, Marshall JL, Pishvaian MJ. A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. J Pancreat Cancer 2019;5:12-21. [PMID: 31065624 DOI: 10.1089/pancan.2019.0003] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
575 Buscail L, Culetto A, Mokhrane FZ, Napoléon B, Meyrignac O, Molinier B, Lebrin M, Bournet B, Bérard E, Canivet C. Endoscopic ultrasound as a reliable tool for assessment of pancreatic adenocarcinoma treatment: Example of in situ gene therapy. Endosc Int Open 2022;10:E910-6. [PMID: 35692905 DOI: 10.1055/a-1799-7774] [Reference Citation Analysis]
576 Tsutsumi C, Abe T, Shinkawa T, Nishihara K, Tamiya S, Nakano T. Long-term survival after hepatectomy for metachronous liver metastasis of pancreatic ductal adenocarcinoma: a case report. Surg Case Rep 2020;6:157. [PMID: 32621095 DOI: 10.1186/s40792-020-00924-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
577 Wu F. High intensity focused ultrasound: A noninvasive therapy for locally advanced pancreatic cancer. World J Gastroenterol 2014; 20(44): 16480-16488 [PMID: 25469016 DOI: 10.3748/wjg.v20.i44.16480] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
578 Dhayat SA, Yang Z. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. J Cancer Res Clin Oncol 2020;146:1625-45. [PMID: 32338295 DOI: 10.1007/s00432-020-03219-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
579 Lamarca A, Foster L, Valle JW, Satyadas T, Siriwardena A. FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out? ESMO Open 2020;5:e000633. [PMID: 33122352 DOI: 10.1136/esmoopen-2019-000633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
580 Ding Y, Jiang J, Xu J, Chen Y, Zheng Y, Jiang W, Mao C, Jiang H, Bao X, Shen Y, Li X, Teng L, Xu N. Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis. ESMO Open 2022;7:100407. [DOI: 10.1016/j.esmoop.2022.100407] [Reference Citation Analysis]
581 Amin S, Baine MJ, Meza JL, Lin C. The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National Cancer Database. Front Oncol 2020;10:1518. [PMID: 32983998 DOI: 10.3389/fonc.2020.01518] [Reference Citation Analysis]
582 Mielgo A, Schmid MC. Impact of tumour associated macrophages in pancreatic cancer. BMB Rep 2013;46:131-8. [PMID: 23527856 DOI: 10.5483/bmbrep.2013.46.3.036] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 6.0] [Reference Citation Analysis]
583 Leal AS, Sporn MB, Pioli PA, Liby KT. The triterpenoid CDDO-imidazolide reduces immune cell infiltration and cytokine secretion in the KrasG12D;Pdx1-Cre (KC) mouse model of pancreatic cancer. Carcinogenesis. 2016;37:1170-1179. [PMID: 27659181 DOI: 10.1093/carcin/bgw099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
584 Wode K, Hök Nordberg J, Kienle GS, Elander NO, Bernhardson BM, Sunde B, Sharp L, Henriksson R, Fransson P. Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL). Trials 2020;21:783. [PMID: 32917288 DOI: 10.1186/s13063-020-04581-y] [Reference Citation Analysis]
585 Thomas D, Radhakrishnan P. Role of Tumor and Stroma-Derived IGF/IGFBPs in Pancreatic Cancer. Cancers (Basel) 2020;12:E1228. [PMID: 32414222 DOI: 10.3390/cancers12051228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
586 Miller CS, Barkun AN, Martel M, Chen YI. Endoscopic ultrasound-guided biliary drainage for distal malignant obstruction: a systematic review and meta-analysis of randomized trials. Endosc Int Open 2019;7:E1563-73. [PMID: 31723579 DOI: 10.1055/a-0998-8129] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
587 Winter JM, Tang LH, Klimstra DS, Liu W, Linkov I, Brennan MF, D’Angelica MI, DeMatteo RP, Fong Y, Jarnagin WR. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. Ann Surg. 2013;258:331-335. [PMID: 23360922 DOI: 10.1097/sla.0b013e31827fe9ce] [Cited by in Crossref: 51] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
588 Kumar V, Chaudhary AK, Dong Y, Zhong HA, Mondal G, Lin F, Kumar V, Mahato RI. Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer. Sci Rep 2017;7:1665. [PMID: 28490735 DOI: 10.1038/s41598-017-01942-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
589 Tam VC, Ko YJ, Mittmann N, Cheung MC, Kumar K, Hassan S, Chan KK. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol. 2013;20:e90-e106. [PMID: 23559890 DOI: 10.3747/co.20.1223] [Cited by in Crossref: 28] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
590 Ramaker RC, Hardigan AA, Gordon ER, Wright CA, Myers RM, Cooper SJ. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition. BMC Cancer 2021;21:632. [PMID: 34049503 DOI: 10.1186/s12885-021-08388-1] [Reference Citation Analysis]
591 Capello M, Fahrmann JF, Rios Perez MV, Vykoukal JV, Irajizad E, Tripathi SC, Roife D, Bantis LE, Kang Y, Kundnani DL, Xu H, Prakash LR, Long JP, Katayama H, Fleury A, Ferri-Borgogno S, Baluya DL, Dennison JB, Aguilar-Bonavides C, Casabar JP, Celiktas M, Do KA, Fiehn O, Maitra A, Wang H, Feng Z, Chiao PJ, Katz MH, Fleming JB, Hanash SM. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. JCO Precis Oncol 2020;4:426-36. [PMID: 35050739 DOI: 10.1200/PO.19.00330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
592 Faluyi OO, Connor JL, Chatterjee M, Ikin C, Wong H, Palmer DH. Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre. Br J Cancer 2017;116:424-31. [PMID: 28081546 DOI: 10.1038/bjc.2016.406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
593 Li Y, Sarkar FH. MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer. Int J Biol Sci. 2016;12:326-337. [PMID: 26929739 DOI: 10.7150/ijbs.15017] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 7.2] [Reference Citation Analysis]
594 Brunetto E, De Monte L, Balzano G, Camisa B, Laino V, Riba M, Heltai S, Bianchi M, Bordignon C, Falconi M, Bondanza A, Doglioni C, Protti MP. The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer. J Immunother Cancer 2019;7:45. [PMID: 30760333 DOI: 10.1186/s40425-019-0521-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
595 Mori H, Tanoue S, Takaji R, Ueda S, Okahara M, Ueda SS. Arterial Administration of DNA Crosslinking Agents with Restraint of Homologous Recombination Repair by Intravenous Low-Dose Gemcitabine Is Effective for Locally Advanced Pancreatic Cancer. Cancers (Basel) 2022;14:220. [PMID: 35008384 DOI: 10.3390/cancers14010220] [Reference Citation Analysis]
596 Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G. State of the art biological therapies in pancreatic cancer. World J Gastrointest Oncol 2016; 8(1): 55-66 [PMID: 26798437 DOI: 10.4251/wjgo.v8.i1.55] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
597 Takumoto Y, Sasahara Y, Narimatsu H, Akazawa M. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis. JAMA Netw Open 2022;5:e2145515. [PMID: 35099549 DOI: 10.1001/jamanetworkopen.2021.45515] [Reference Citation Analysis]
598 Nikas IP, Mountzios G, Sydney GI, Ioakim KJ, Won J, Papageorgis P. Evaluating Pancreatic and Biliary Neoplasms with Small Biopsy-Based Next Generation Sequencing (NGS): Doing More with Less. Cancers 2022;14:397. [DOI: 10.3390/cancers14020397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
599 Han B, Kim BJ, Kim HS, Choi DR, Shim BY, Lee KH, Kim JW, Kim JH, Song H, Kim JH, Park CK, Lee JW, Kim MJ, Zang DY. A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. J Cancer 2021;12:912-7. [PMID: 33403047 DOI: 10.7150/jca.50514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
600 Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, Singhi AD, Bao P, Bartlett DL, Liotta LA, Espina V, Loughran P, Lotze MT, Zeh HJ. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol. 2015;22:4402-4410. [PMID: 25905586 DOI: 10.1245/s10434-015-4566-4] [Cited by in Crossref: 108] [Cited by in F6Publishing: 104] [Article Influence: 15.4] [Reference Citation Analysis]
601 Lu J, Roy B, Anderson M, Leggett CL, Levy MJ, Pogue B, Hasan T, Wang KK. Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment. J Biomed Opt 2019;24:1-11. [PMID: 31741351 DOI: 10.1117/1.JBO.24.11.118001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
602 Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, Laheru D, Wolfgang CL, Williams T, Bloomston M, Moore MJ, Wei A, Zalupski MM. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 2013;119:2692-700. [PMID: 23720019 DOI: 10.1002/cncr.28117] [Cited by in Crossref: 119] [Cited by in F6Publishing: 104] [Article Influence: 13.2] [Reference Citation Analysis]
603 Cowzer D, Harding JJ. Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments. Cancers 2022;14:1800. [DOI: 10.3390/cancers14071800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
604 Sahin IH, Elias H, Chou JF, Capanu M, O'Reilly EM. Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior. BMC Cancer 2018;18:769. [PMID: 30055578 DOI: 10.1186/s12885-018-4679-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
605 Ueno M, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, Furukawa M, Okusaka T, Kawabe K, Furuse J, Komatsu Y, Ishii H, Sato A, Shimizu S, Chugh P, Tang R, Ioka T. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Cancer Med 2020;9:9396-408. [PMID: 33099898 DOI: 10.1002/cam4.3558] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
606 Berger AK, Haag GM, Ehmann M, Byl A, Jäger D, Springfeld C. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. BMC Gastroenterol 2017;17:143. [PMID: 29207968 DOI: 10.1186/s12876-017-0709-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
607 Awasthi N, Scire E, Monahan S, Grojean M, Zhang E, Schwarz MA, Schwarz RE. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models. Oncotarget. 2016;7:46988-47001. [PMID: 27127884 DOI: 10.18632/oncotarget.9029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
608 Tao Z, Muzumdar MD, Detappe A, Huang X, Xu ES, Yu Y, Mouhieddine TH, Song H, Jacks T, Ghoroghchian PP. Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. Nano Lett 2018;18:2195-208. [PMID: 29533667 DOI: 10.1021/acs.nanolett.7b04043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
609 Frigeri M, De Dosso S, Castillo-Fernandez O, Feuerlein K, Neuenschwander H, Saletti P. Chemotherapy in patients with advanced pancreatic cancer: too close to death? Support Care Cancer 2013;21:157-63. [PMID: 22648205 DOI: 10.1007/s00520-012-1505-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
610 Okano N, Matsuki R, Toki M, Gondo K, Ochiai K, Watanabe S, Tateishi H, Kogure M, Suzuki Y, Sugiyama M, Nagashima F, Shibahara J, Sakamoto Y, Furuse J. A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer. Intern Med 2022. [PMID: 35793961 DOI: 10.2169/internalmedicine.9504-22] [Reference Citation Analysis]
611 Gu D, Lin H, Zhang X, Fan Q, Chen S, Shahda S, Liu Y, Sun J, Xie J. Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. Cancers (Basel) 2018;10:E403. [PMID: 30373214 DOI: 10.3390/cancers10110403] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
612 White RR, Murphy JD, Martin RCG. The Landmark Series: Locally Advanced Pancreatic Cancer and Ablative Therapy Options. Ann Surg Oncol 2021;28:4173-80. [PMID: 33586072 DOI: 10.1245/s10434-021-09662-z] [Reference Citation Analysis]
613 Sheahan AV, Biankin AV, Parish CR, Khachigian LM. Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget 2018;9:21613-27. [PMID: 29765563 DOI: 10.18632/oncotarget.25085] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
614 Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. Neoplasia. 2015;17:757-766. [PMID: 26585231 DOI: 10.1016/j.neo.2015.09.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
615 Lu W, Wang L, Lou J, Tang K. Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions. Tumori 2022;:3008916221110265. [PMID: 35815545 DOI: 10.1177/03008916221110265] [Reference Citation Analysis]
616 Hue JJ, Bingmer K, Sugumar K, Markt SC, Rothermel LD, Hardacre JM, Ammori JB, Winter JM, Ocuin LM. Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. J Pancreat Cancer 2021;7:31-8. [PMID: 33937617 DOI: 10.1089/pancan.2021.0003] [Reference Citation Analysis]
617 Tramontano AC, Chen Y, Watson TR, Eckel A, Sheehan DF, Peters MLB, Pandharipande PV, Hur C, Kong CY. Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. Medicine (Baltimore) 2019;98:e18082. [PMID: 31804317 DOI: 10.1097/MD.0000000000018082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
618 Michael N, Beale G, O'Callaghan C, Melia A, DeSilva W, Costa D, Kissane D, Shapiro J, Hiscock R. Timing of palliative care referral and aggressive cancer care toward the end-of-life in pancreatic cancer: a retrospective, single-center observational study. BMC Palliat Care 2019;18:13. [PMID: 30691417 DOI: 10.1186/s12904-019-0399-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
619 Yoo C, Kang J, Kim KP, Lee JL, Ryoo BY, Chang HM, Lee SS, Park DH, Song TJ, Seo DW. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Oncotarget. 2017;8:46337-46347. [PMID: 28564637 DOI: 10.18632/oncotarget.17940] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
620 Kalloger SE, Riazy M, Tessier-Cloutier B, Karasinska JM, Gao D, Peixoto RD, Samimi S, Chow C, Wong HL, Mackey JR, Renouf DJ, Schaeffer DF. A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine. J Pathol Clin Res 2017;3:179-90. [PMID: 28770102 DOI: 10.1002/cjp2.75] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
621 Kimura J, Ono HA, Kosaka T, Nagashima Y, Hirai S, Ohno S, Aoki K, Julia D, Yamamoto M, Kunisaki C, Endo I. Conditionally replicative adenoviral vectors for imaging the effect of chemotherapy on pancreatic cancer cells. Cancer Sci 2013;104:1083-90. [PMID: 23679574 DOI: 10.1111/cas.12196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
622 Kawano M, Kaino S, Amano S, Shinoda S, Suenaga S, Sen-Yo M, Sakaida I. Heat Shock Protein 27 Expression in EUS-FNA Samples Can Predict Gemcitabine Sensitivity in Pancreatic Cancer. In Vivo. 2018;32:637-642. [PMID: 29695571 DOI: 10.21873/invivo.11286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
623 Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, Malafa MP, Shridhar R, Hodul PJ, Hoffe SE. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncol 2017;56:391-7. [PMID: 27885876 DOI: 10.1080/0284186X.2016.1256497] [Cited by in Crossref: 54] [Cited by in F6Publishing: 27] [Article Influence: 10.8] [Reference Citation Analysis]
624 Martin-Perez E, Domínguez-Muñoz JE, Botella-Romero F, Cerezo L, Matute Teresa F, Serrano T, Vera R. Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. Clin Transl Oncol 2020;22:1963-75. [PMID: 32318964 DOI: 10.1007/s12094-020-02350-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
625 Zerbi A, Nappo G. The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: What should be the surgeon's choice? Endosc Ultrasound 2017;6:S87-9. [PMID: 29387699 DOI: 10.4103/eus.eus_69_17] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
626 Sasaki Y, Hamada K, Kaneta T, Takahashi T, Kubota Y, Ishida H, Ichikawa W. Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? Cancer Sci 2015;106:1100. [PMID: 26268893 DOI: 10.1111/cas.12708] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
627 Turner A, Bond DR, Vuong QV, Chalmers A, Beckett EL, Weidenhofer J, Scarlett CJ. Elaeocarpus reticulatus fruit extracts reduce viability and induce apoptosis in pancreatic cancer cells in vitro. Mol Biol Rep 2020;47:2073-84. [PMID: 32065323 DOI: 10.1007/s11033-020-05307-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
628 Malgerud L, Lindberg J, Wirta V, Gustafsson-Liljefors M, Karimi M, Moro CF, Stecker K, Picker A, Huelsewig C, Stein M, Bohnert R, Del Chiaro M, Haas SL, Heuchel RL, Permert J, Maeurer MJ, Brock S, Verbeke CS, Engstrand L, Jackson DB, Grönberg H, Löhr JM. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Mol Oncol 2017;11:1413-29. [PMID: 28675654 DOI: 10.1002/1878-0261.12108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
629 Li J, Li X, Bai C, Yang K; Cochrane Gut Group. Neoadjuvant chemotherapy or chemoradiotherapy versus upfront surgery alone for resectable or borderline resectable pancreatic cancer. Cochrane Database of Systematic Reviews 2021;2021. [DOI: 10.1002/14651858.cd014618] [Reference Citation Analysis]
630 Park SJ, Kim H, Shin K, Lee MA, Hong TH. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol 2019; 11(11): 1021-1030 [PMID: 31798782 DOI: 10.4251/wjgo.v11.i11.1021] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
631 Zhao Q, Zheng Y, Lv X, Gong J, Yang L. IMB5036 inhibits human pancreatic cancer growth primarily through activating necroptosis. Basic Clin Pharmacol Toxicol 2021. [PMID: 34841678 DOI: 10.1111/bcpt.13694] [Reference Citation Analysis]
632 Pham TND, Shields MA, Spaulding C, Principe DR, Li B, Underwood PW, Trevino JG, Bentrem DJ, Munshi HG. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Cancers (Basel) 2021;13:440. [PMID: 33503832 DOI: 10.3390/cancers13030440] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
633 Mizuma M, Rasheed ZA, Yabuuchi S, Omura N, Campbell NR, de Wilde RF, De Oliveira E, Zhang Q, Puig O, Matsui W. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol Cancer Ther. 2012;11:1999-2009. [PMID: 22752426 DOI: 10.1158/1535-7163.mct-12-0017] [Cited by in Crossref: 58] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
634 Tajima H, Ohta T, Okazaki M, Yamaguchi T, Ohbatake Y, Okamoto K, Nakanuma S, Kinoshita J, Makino I, Nakamura K, Miyashita T, Takamura H, Ninomiya I, Fushida S, Nakamura H. Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer. Mol Clin Oncol 2019;11:157-66. [PMID: 31281650 DOI: 10.3892/mco.2019.1867] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
635 Catalano M, Conca R, Petrioli R, Ramello M, Roviello G. FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer. Cancer Manag Res. 2020;12:10271-10278. [PMID: 33116881 DOI: 10.2147/cmar.s267393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
636 Pellino A, Loupakis F, Cadamuro M, Dadduzio V, Fassan M, Guido M, Cillo U, Indraccolo S, Fabris L. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol 2018;3:40. [PMID: 30148225 DOI: 10.21037/tgh.2018.07.02] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
637 Uemura S, Iwashita T, Ichikawa H, Iwasa Y, Mita N, Shiraki M, Shimizu M. Impact of Controlling nutritional status (CONUT) in patients with unresectable advanced pancreatic cancer receiving multi-agent chemotherapy: A single center, retrospective cohort study. Pancreatology 2022. [DOI: 10.1016/j.pan.2022.01.010] [Reference Citation Analysis]
638 Singh RR, O'Reilly EM. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. Drugs 2020;80:647-69. [PMID: 32306207 DOI: 10.1007/s40265-020-01304-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
639 AlMasri S, Zenati M, Hammad A, Nassour I, Liu H, Hogg ME, Zeh HJ, Boone B, Bahary N, Singhi AD, Lee KK, Paniccia A, Zureikat AH. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. JAMA Netw Open 2022;5:e2218355. [PMID: 35737385 DOI: 10.1001/jamanetworkopen.2022.18355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
640 Klimant E, Markman M, Albu DM. Clinically meaningful responses to sequential gemcitabine-based chemotherapy regimens in a patient with metastatic pancreatic cancer. Case Rep Oncol 2013;6:72-7. [PMID: 23466899 DOI: 10.1159/000346836] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
641 White MN, Dotan E, Catalano PJ, Cardin DB, Berlin JD. Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients. J Geriatr Oncol 2019;10:540-6. [PMID: 30573201 DOI: 10.1016/j.jgo.2018.11.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
642 Sunami Y, Böker V, Kleeff J. Targeting and Reprograming Cancer-Associated Fibroblasts and the Tumor Microenvironment in Pancreatic Cancer. Cancers (Basel) 2021;13:697. [PMID: 33572223 DOI: 10.3390/cancers13040697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
643 Kokkali S, Tripodaki ES, Drizou M, Stefanou D, Magou E, Zylis D, Kapiris M, Nasi D, Georganta C, Ardavanis A. Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer. In Vivo 2018;32:653-7. [PMID: 29695574 DOI: 10.21873/invivo.11289] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
644 Tummers WS, Groen JV, Sibinga Mulder BG, Farina-Sarasqueta A, Morreau J, Putter H, van de Velde CJ, Vahrmeijer AL, Bonsing BA, Mieog JS, Swijnenburg RJ. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br J Surg. 2019;106:1055-1065. [PMID: 30883699 DOI: 10.1002/bjs.11115] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 21.0] [Reference Citation Analysis]
645 Pan CH, Otsuka Y, Sridharan B, Woo M, Leiton CV, Babu S, Torrente Gonçalves M, Kawalerski RR, K Bai JD, Chang DK, Biankin AV, Scampavia L, Spicer T, Escobar-Hoyos LF, Shroyer KR. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Mol Oncol 2020;14:1800-16. [PMID: 32533886 DOI: 10.1002/1878-0261.12743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
646 Abdel Hadi N, Reyes-Castellanos G, Carrier A. Targeting Redox Metabolism in Pancreatic Cancer. Int J Mol Sci 2021;22:1534. [PMID: 33546421 DOI: 10.3390/ijms22041534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
647 Liu H, Shi Y, Qian F. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. Adv Drug Deliv Rev 2021;172:37-51. [PMID: 33705881 DOI: 10.1016/j.addr.2021.02.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
648 Yang SH, Lee JC, Guo JC, Kuo SH, Tien YW, Kuo TC, Cheng AL, Yeh KH. Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. PLoS One 2017;12:e0180628. [PMID: 28678832 DOI: 10.1371/journal.pone.0180628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
649 Lan W, Bian B, Xia Y, Dou S, Gayet O, Bigonnet M, Santofimia-Castaño P, Cong M, Peng L, Dusetti N, Iovanna J. E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments. Sci Rep 2018;8:8330. [PMID: 29844366 DOI: 10.1038/s41598-018-26613-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
650 Aprile G, Rihawi K, De Carlo E, Sonis ST. Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. World J Gastroenterol 2015; 21(41): 11793-11803 [PMID: 26557003 DOI: 10.3748/wjg.v21.i41.11793] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
651 Suzuki T, Otsuka M, Seimiya T, Iwata T, Kishikawa T, Koike K. The biological role of metabolic reprogramming in pancreatic cancer. MedComm (2020) 2020;1:302-10. [PMID: 34766124 DOI: 10.1002/mco2.37] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
652 Tang X, Du X, Yu Y, Qin M, Qian L, Zhang M, Yang Y, Yu Q, Gan Z. Deep-Penetrating Triple-Responsive Prodrug Nanosensitizer Actuates Efficient Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma Models. Small 2022;:e2202834. [PMID: 35808966 DOI: 10.1002/smll.202202834] [Reference Citation Analysis]
653 Mohammad AA. Advanced pancreatic cancer: The standard of care and new opportunities. Oncol Rev 2018;12:370. [PMID: 30344961 DOI: 10.4081/oncol.2018.370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
654 Pan P, Skaer C, Yu J, Zhao H, Ren H, Oshima K, Wang LS. Berries and other natural products in the pancreatic cancer chemoprevention in human clinical trials. J Berry Res 2017;7:147-61. [PMID: 29367867 DOI: 10.3233/JBR-170159] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 6.6] [Reference Citation Analysis]
655 Nagasaki Y, Yamane H, Ochi N, Honda Y, Takigawa N. High Uptake of FDG Along a Biliary Stent. Clin Nucl Med 2016;41:890-1. [PMID: 27607171 DOI: 10.1097/RLU.0000000000001357] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
656 Li D, Pant S, Ryan DP, Laheru D, Bahary N, Dragovich T, Hosein PJ, Rolfe L, Saif MW, LaValle J, Yu KH, Lowery MA, Allen A, O'Reilly EM. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. Pancreatology 2014;14:398-402. [PMID: 25278310 DOI: 10.1016/j.pan.2014.07.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
657 Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprani D, Esposito A, Landoni L, Casetti L, Tuveri M, Paiella S, Casciani F, Sereni E, Binco A, Bonamini D, Secchettin E, Auriemma A, Merz V, Simionato F, Zecchetto C, D'Onofrio M, Melisi D, Bassi C, Salvia R. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surg 2019;154:932-42. [PMID: 31339530 DOI: 10.1001/jamasurg.2019.2277] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
658 Valero V 3rd, Saunders TJ, He J, Weiss MJ, Cameron JL, Dholakia A, Wild AT, Shin EJ, Khashab MA, O'Broin-Lennon AM, Ali SZ, Laheru D, Hruban RH, Iacobuzio-Donahue CA, Herman JM, Wolfgang CL. Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management. Ann Surg 2016;263:153-61. [PMID: 26020105 DOI: 10.1097/SLA.0000000000001156] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
659 Zhang Z, Song J, Xie C, Pan J, Lu W, Liu M. Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials. AAPS J 2021;23:29. [PMID: 33580411 DOI: 10.1208/s12248-021-00556-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
660 Leen E, Picard J, Stebbing J, Abel M, Dhillon T, Wasan H. Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. J Gastrointest Oncol. 2018;9:275-281. [PMID: 29755766 DOI: 10.21037/jgo.2018.01.14] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
661 Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 2014;43:343-9. [PMID: 24622062 DOI: 10.1097/MPA.0000000000000095] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
662 Dardare J, Witz A, Merlin JL, Bochnakian A, Toussaint P, Gilson P, Harlé A. Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities. Pharmaceuticals (Basel) 2021;14:740. [PMID: 34451837 DOI: 10.3390/ph14080740] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
663 Chou A, Froio D, Nagrial AM, Parkin A, Murphy KJ, Chin VT, Wohl D, Steinmann A, Stark R, Drury A, Walters SN, Vennin C, Burgess A, Pinese M, Chantrill LA, Cowley MJ, Molloy TJ, Waddell N, Johns A, Grimmond SM, Chang DK, Biankin AV, Sansom OJ, Morton JP, Grey ST, Cox TR, Turchini J, Samra J, Clarke SJ, Timpson P, Gill AJ, Pajic M; Australian Pancreatic Cancer Genome Initiative (APGI). Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut 2018;67:2142-55. [PMID: 29080858 DOI: 10.1136/gutjnl-2017-315144] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 17.8] [Reference Citation Analysis]
664 Hartwig W, Büchler MW. Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. Gastrointest Tumors 2013;1:41-52. [PMID: 26673950 DOI: 10.1159/000354992] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
665 Zhou Y, Liao S, You J, Wu H. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature. Updates Surg 2021. [PMID: 34021484 DOI: 10.1007/s13304-021-01089-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
666 Rosenberg A, Mahalingam D. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. J Gastrointest Oncol. 2018;9:143-159. [PMID: 29564181 DOI: 10.21037/jgo.2018.01.13] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
667 Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol Cancer Ther. 2013;12:2213-2225. [PMID: 23918833 DOI: 10.1158/1535-7163.mct-13-0104] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
668 Yamada Y, Fujii H, Watanabe D, Kato-Hayashi H, Ohata K, Kobayashi R, Ishihara T, Uemura S, Iwashita T, Shimizu M, Suzuki A. Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy. Cancers (Basel). 2018;10. [PMID: 30453583 DOI: 10.3390/cancers10110454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
669 Young K, Hughes DJ, Cunningham D, Starling N. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. Ther Adv Med Oncol. 2018;10:1758835918816281. [PMID: 30574212 DOI: 10.1177/1758835918816281] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
670 Manrai M, Tilak TVSVGK, Dawra S, Srivastava S, Singh A. Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. World J Gastroenterol 2021; 27(39): 6572-6589 [PMID: 34754153 DOI: 10.3748/wjg.v27.i39.6572] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
671 Hamada T, Khalaf N, Yuan C, Morales-Oyarvide V, Babic A, Nowak JA, Qian ZR, Ng K, Rubinson DA, Kraft P, Giovannucci EL, Stampfer MJ, Fuchs CS, Ogino S, Wolpin BM. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2018;16:1300-1306.e3. [PMID: 29474971 DOI: 10.1016/j.cgh.2018.02.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
672 Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer 2018;4:418-28. [PMID: 29860986 DOI: 10.1016/j.trecan.2018.04.001] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 20.3] [Reference Citation Analysis]
673 Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2784-2796. [PMID: 27247222 DOI: 10.1200/jco.2016.67.1412] [Cited by in Crossref: 166] [Cited by in F6Publishing: 90] [Article Influence: 27.7] [Reference Citation Analysis]
674 Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016;45:370-375. [PMID: 26390428 DOI: 10.1097/mpa.0000000000000458] [Cited by in Crossref: 122] [Cited by in F6Publishing: 84] [Article Influence: 20.3] [Reference Citation Analysis]
675 Kim JS, Park JY, Choi M, Joo DJ, Hwang HK, Lee WJ, Kang CM. Pancreaticoduodenectomy with combined hepatic artery and portal vein resection after laparoscopic division of pancreaticosplenic ligament due to FOLFIRINOX-induced hepatic toxicity related secondary hypersplenism. Ann Hepatobiliary Pancreat Surg 2021;25:307-12. [PMID: 34053937 DOI: 10.14701/ahbps.2021.25.2.307] [Reference Citation Analysis]
676 Lenzo FL, Kato S, Pabla S, DePietro P, Nesline MK, Conroy JM, Burgher B, Glenn ST, Kuvshinoff B, Kurzrock R, Morrison C. Immune profiling and immunotherapeutic targets in pancreatic cancer. Ann Transl Med 2021;9:119. [PMID: 33569421 DOI: 10.21037/atm-20-1076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
677 Kang BW, Chau I. Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. Expert Opin Investig Drugs 2021;:1-19. [PMID: 34727804 DOI: 10.1080/13543784.2021.1995354] [Reference Citation Analysis]
678 Zhao S, Devega R, Francois A, Kidane D. Human ALKBH6 Is Required for Maintenance of Genomic Stability and Promoting Cell Survival During Exposure of Alkylating Agents in Pancreatic Cancer. Front Genet 2021;12:635808. [PMID: 33897761 DOI: 10.3389/fgene.2021.635808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
679 Zdenkowski N, Radvan G, Pugliese L, Charlton J, Oldmeadow C, Fraser A, Bonaventura A. Treatment of pancreatic insufficiency using pancreatic extract in patients with advanced pancreatic cancer: a pilot study (PICNIC). Support Care Cancer 2017;25:1963-71. [DOI: 10.1007/s00520-017-3602-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
680 De Simoni O, Scarpa M, Tonello M, Pilati P, Tolin F, Spolverato Y, Gruppo M. Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. Cancers (Basel) 2020;12:E3402. [PMID: 33213022 DOI: 10.3390/cancers12113402] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
681 Chen CY, Liang SH, Su YY, Chiang NJ, Wang HC, Chiu CF, Chen LT, Bai LY. Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan. PLoS One 2020;15:e0244487. [PMID: 33373398 DOI: 10.1371/journal.pone.0244487] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
682 Singh H, Perez K, Wolpin BM, Aguirre AJ. Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. J Clin Oncol 2021;39:3199-206. [PMID: 34428095 DOI: 10.1200/JCO.21.01510] [Reference Citation Analysis]
683 Jiang Z, Chen X, Chen K, Sun L, Gao L, Zhou C, Lei M, Duan W, Wang Z, Ma Q, Ma J. YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine. Nutrients 2016;8:E546. [PMID: 27669292 DOI: 10.3390/nu8100546] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
684 Rahal MM, Bazarbashi SN, Kandil MS, Al-Shehri AS, Alzahrani AM, Aljubran AH, Zekri JE, Al Olayan AA, Alsharm AA, Kabbani MA, Fagih MA; Saudi Oncology Society. Saudi Oncology Society clinical management guideline series. Pancreatic cancer 2014. Saudi Med J 2014;35:1534-7. [PMID: 25491225] [Reference Citation Analysis]
685 Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, Kopek N, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol 2016;23:e605-14. [PMID: 28050151 DOI: 10.3747/co.23.3394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
686 Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M, Bekaii-Saab T, Lesinski GB. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clin Cancer Res 2016;22:2565-74. [PMID: 26719427 DOI: 10.1158/1078-0432.CCR-15-1732] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
687 Brunetti O, Russo A, Scarpa A, Santini D, Reni M, Bittoni A, Azzariti A, Aprile G, Delcuratolo S, Signorile M, Gnoni A, Palermo L, Lorusso V, Cascinu S, Silvestris N. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Oncotarget 2015;6:23323-41. [PMID: 26259238 DOI: 10.18632/oncotarget.4492] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 7.2] [Reference Citation Analysis]
688 Cheng J, Cashman JR. PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin β3-KRAS-dependent pancreatic cancer stem cells. Sci Rep 2020;10:9162. [PMID: 32514015 DOI: 10.1038/s41598-020-65804-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
689 Lo Re G, Santeufemia DA, Foltran L, Bidoli E, Basso SM, Lumachi F. Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience. Oncotarget 2015;6:8255-60. [PMID: 25779664 DOI: 10.18632/oncotarget.3143] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [